Data / Research funding / Gene Therapy
Gene Therapy: 2,023 NIH awards ($2.4B) to 454 organizations
2,023 NIH awards ($2.4B) in the NIH spending category Gene Therapy, to 454 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 2,023 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| A non-viral CRISPR-mediated genome editing delivery platform as a potential therapy for neurogenetic diseases | NIH | National Center for Advancing Translational Sciences | 2023 to 2025 | $26,526,303 | September 20, 2023 | July 31, 2027 | JIANG, YONG-HUI | reporter.nih.gov |
| Guide RNA manufacturing capabilities for platform in vivo base editing therapies for metabolic liver diseases | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $17,556,074 | August 1, 2023 | July 31, 2028 | PERANTEAU, WILLIAM H. | reporter.nih.gov |
| Replication Study of Off-Target Assays for Guide RNAs in CRISPR-Based Therapeutics | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $17,077,732 | December 1, 2024 | April 30, 2025 | SAHA, KRISHANU | reporter.nih.gov |
| Therapeutic Editing to Lower PrP in Prion Disease | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $15,507,691 | May 17, 2023 | April 30, 2026 | VALLABH, SONIA MINIKEL | reporter.nih.gov |
| Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $14,843,451 | August 20, 2021 | May 31, 2028 | NAJI, ALI | reporter.nih.gov |
| Admin. Supp.: Correction of Neurological Disease via Allele Specific Excision of Pathogenic Repeats | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $13,703,967 | May 15, 2023 | April 30, 2028 | DOUDNA, JENNIFER A | reporter.nih.gov |
| Personalized Modeling of CAR-T Cell Immunotherapy Using iPSC-Derived Effectors and Patient- Derived Tumor Organoids | NIH | National Cancer Institute | 2023 to 2025 | $12,675,268 | March 1, 1997 | August 31, 2026 | LIBUTTI, STEVEN K. | reporter.nih.gov |
| A Safety and Efficacy Study of AAV2-hAADC for AADC Deficiency | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $12,060,518 | September 15, 2016 | August 31, 2027 | BANKIEWICZ, KRYSTOF S | reporter.nih.gov |
| Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA. | NIH | National Institute on Aging | 2022 to 2025 | $10,320,460 | February 15, 2022 | January 31, 2027 | AGADJANYAN, MICHAEL G | reporter.nih.gov |
| Nonhuman Primate Testing Center for Evaluation of Somatic Cell Genome Editing Tools: Antibodies Supplement | NIH | Office of the Director, National Institutes of Health | 2021 to 2023 | $10,154,758 | April 14, 2023 | March 31, 2025 | TARANTAL, ALICE F | reporter.nih.gov |
| Silence ALS: A Platform for the Discovery and Development of Antisense Therapeutics for Patients with Ultra-Rare Forms of ALS | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $9,796,602 | March 1, 2024 | February 28, 2027 | SHNEIDER, NEIL ALAN | reporter.nih.gov |
| Dissemination and Coordinating Center for the SCGE Consortium | NIH | National Human Genome Research Institute | 2021 to 2023 | $9,585,373 | February 1, 2019 | November 30, 2025 | DWINELL, MELINDA R | reporter.nih.gov |
| Therapeutic gene editing and multimodal imaging in juvenile macular degeneration | NIH | National Eye Institute | 2021 to 2024 | $8,710,741 | June 1, 2020 | May 31, 2026 | TSANG, STEPHEN H | reporter.nih.gov |
| Restoring Vision with High-Fidelity Nonsense Codon Correction | NIH | National Eye Institute | 2021 to 2025 | $7,812,597 | February 1, 2021 | November 30, 2026 | PATTNAIK, BIKASH RANJAN | reporter.nih.gov |
| Open-Access AAV Toolbox for Basal Ganglia Cell Types and Circuits | NIH | National Institute of Mental Health | 2021 | $7,282,237 | September 16, 2021 | September 15, 2024 | TASIC, BOSILJKA | reporter.nih.gov |
| Swine Somatic Cell Genome Editing (SCGE) Center | NIH | Office of the Director, National Institutes of Health | 2021 to 2023 | $7,052,414 | June 1, 2019 | May 31, 2025 | WELLS, KEVIN DALE | reporter.nih.gov |
| NATIONAL INSTITUTE OF HEALTH (NIH), NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCE (NCATS), BESPOKE GENE THERAPY CONSORTIUM, COORDINATION CENTER, GENE THERAPY ASSET DEVELOPMENT AND PLATFORM OPERA | NIH | Office of the Director, National Institutes of Health | 2022 to 2025 | $6,908,005 | July 2, 2024 | August 31, 2026 | reporter.nih.gov | |
| Personalized prime editing as a platform for hepatic inborn errors of metabolism | NIH | National Center for Advancing Translational Sciences | 2024 to 2025 | $6,886,793 | September 20, 2024 | August 31, 2028 | AHRENS-NICKLAS, REBECCA CLARE | reporter.nih.gov |
| Cell type specific AAVs to study reward and cognition | NIH | National Institute of Mental Health | 2022 | $6,850,168 | September 1, 2022 | August 31, 2025 | STAUFFER, WILLIAM RICHARD | reporter.nih.gov |
| An Intranasal GDNF Gene Therapy for Opioid Relapse Reduction | NIH | National Institute on Drug Abuse | 2021 | $6,693,512 | September 15, 2021 | August 31, 2025 | WASZCZAK, BARBARA LEE | reporter.nih.gov |
| Precision Editing of Granulin Mutations that Cause Frontotemporal Dementia | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $6,580,415 | August 15, 2025 | July 31, 2029 | SONTHEIMER, ERIK J. | reporter.nih.gov |
| AAV-mediated editing to treat human autosomal dominant hearing loss DFNA41 and DFNA2 | NIH | National Center for Advancing Translational Sciences | 2024 to 2025 | $6,541,622 | September 20, 2024 | August 31, 2028 | CHEN, ZHENG-YI | reporter.nih.gov |
| Engineered AAV Identification, Validation, and Dissemination Pipeline for Brain Cell Type-Specific Manipulation Across Species | NIH | National Institute of Mental Health | 2021 | $6,133,641 | September 20, 2021 | September 19, 2025 | GRADINARU, VIVIANA | reporter.nih.gov |
| S4 TO 108 NCATS GENE THERAPY VECTOR | NIH | Office of the Director, National Institutes of Health | 2021 to 2023 | $6,133,050 | September 30, 2021 | September 29, 2024 | KOROLEVA, ANNA | reporter.nih.gov |
| Phase IA/IB Study of AAVrh.10hFXN Therapy to Treat the Cardiomyopathy of Friedreich's Ataxia | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $5,884,638 | August 1, 2020 | August 31, 2025 | CRYSTAL, RONALD G | reporter.nih.gov |
| Advancing RNA Therapeutics for Huntington’s Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $5,226,511 | February 1, 2020 | January 31, 2026 | ARONIN, NEIL | reporter.nih.gov |
| A Shared Neuroscience Platform for National Dissemination and Training in Brain Organogenesis, Behavioral and Brain Disease Models, Viral Vectors, and Imaging Technologies | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $5,191,106 | June 16, 2022 | May 31, 2027 | SHAMLOO, MEHRDAD | reporter.nih.gov |
| Precision microRNA medicine in cancer | NIH | National Cancer Institute | 2021 to 2025 | $5,120,362 | August 22, 2019 | July 31, 2026 | SLACK, FRANK J. | reporter.nih.gov |
| Human gene transfer & macrophage cell transplantation therapy of hereditary PAP (hPAP) | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $5,061,587 | May 10, 2021 | April 30, 2027 | TRAPNELL, BRUCE C | reporter.nih.gov |
| Engineered Gene Circuits for Basic Science and Biotechnology | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $4,959,754 | August 1, 2004 | August 31, 2029 | HASTY, JEFF M | reporter.nih.gov |
| Evolving Novel AAV Vectors for Gene Therapy to Cure HIV | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,872,750 | June 7, 2022 | May 31, 2027 | SACHA, JONAH B. | reporter.nih.gov |
| Targeted DOK7 gene therapy for Congenital Myasthenic Syndromes | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $4,856,116 | September 15, 2021 | August 31, 2026 | SEPULVEDA, PATRICIO | reporter.nih.gov |
| Translational Coordination and Dissemination Center for the SCGE Consortium | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $4,846,790 | June 1, 2023 | May 31, 2028 | DWINELL, MELINDA R | reporter.nih.gov |
| A Phase I Clinical Trial Testing Feasibility of Hematopoietic Stem Cell Gene Therapy Using Platelet Factor VIII to Safely Improve Hemostasis for Severe Hemophilia A with Inhibitory Antibodies | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $4,780,411 | April 5, 2019 | March 31, 2026 | WILCOX, DAVID ALLEN | reporter.nih.gov |
| Human genetic supplementation without donor DNA or a DNA break | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $4,732,957 | September 30, 2020 | July 31, 2025 | COLLINS, KATHLEEN | reporter.nih.gov |
| Development and validation of AAV vectors to manipulate specific neuronal subtypes and circuits involved in epilepsy and psychiatric disorders across mammalian species. | NIH | National Institute of Mental Health | 2023 to 2024 | $4,681,385 | August 22, 2019 | November 30, 2025 | FISHELL, GORDON J | reporter.nih.gov |
| Novel macrophage-tropic transmitted/founder SHIV model of CNS persistence to evaluate CRISPR/Cas9 gene editing | NIH | National Institute of Mental Health | 2021 to 2025 | $4,668,329 | July 5, 2021 | April 30, 2027 | BAR, KATHARINE JUNE | reporter.nih.gov |
| Preclinical optimization of a gene therapy for erythromelalgia and chronic pain | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $4,279,361 | June 1, 2021 | May 31, 2025 | ALEMAN GUILLEN, FERNANDO | reporter.nih.gov |
| A Clinical Trial of AAV2-BDNF Gene Therapy in Alzheimer's Disease | NIH | National Institute on Aging | 2021 to 2024 | $4,266,904 | May 15, 2021 | April 30, 2027 | TUSZYNSKI, MARK H. | reporter.nih.gov |
| Retinoids in Vision | NIH | National Eye Institute | 2021 to 2025 | $4,266,288 | August 1, 1992 | August 31, 2028 | PALCZEWSKI, KRZYSZTOF | reporter.nih.gov |
| Optimization of an in vivo base editing strategy to treat SOD1-linked ALS | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $4,091,010 | July 25, 2025 | November 30, 2026 | GAJ, THOMAS | reporter.nih.gov |
| Diagnosis, Prevention, And Treatment Of Cardiovascular Diseases With Genome Editing | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,046,250 | March 20, 2019 | February 28, 2026 | MUSUNURU, KIRAN | reporter.nih.gov |
| Base editing and prime editing for sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,000,055 | January 1, 2021 | June 30, 2030 | WEISS, MITCHELL J | reporter.nih.gov |
| NextGen - CRI | NIH | National Cancer Institute | 2022 to 2025 | $3,968,330 | June 1, 2025 | May 31, 2026 | BOLLARD, CATHERINE M. | reporter.nih.gov |
| Preclinical development of breakthrough immunotherapy for brain tumors | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,949,492 | December 15, 2017 | November 30, 2025 | OKADA, HIDEHO | reporter.nih.gov |
| Harnessing engineered T regulatory cells to promote beta cell health in T1D | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $3,920,533 | April 8, 2022 | January 31, 2026 | BUCKNER, JANE HOYT | reporter.nih.gov |
| Next-generation human liver gene therapy | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,896,814 | September 30, 2021 | June 30, 2027 | WILLENBRING, HOLGER | reporter.nih.gov |
| Induction of autophagy to enhance CAR-T cells in HIV cure approaches | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,855,196 | June 25, 2022 | May 31, 2027 | ZHEN, ANJIE | reporter.nih.gov |
| A New and Disruptive Gene Based Therapy for Atrial Fibrillation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $3,849,106 | May 1, 2021 | December 31, 2025 | MOEN, ROBERT CHARLES | reporter.nih.gov |
| Immunomodulation Approaches to Improve Safety And Efficacy of Gene Therapy Treatment in Friedreich’s Ataxia | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,844,243 | May 1, 2021 | August 31, 2026 | CORTI, MANUELA | reporter.nih.gov |
| Models for Therapy of Hereditary Retinal Degeneration | NIH | National Eye Institute | 2021 to 2025 | $3,791,872 | December 1, 1992 | December 31, 2029 | BELTRAN, WILLIAM A. | reporter.nih.gov |
| Natural killer cell engineering to target the HIV reservoir | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,790,684 | April 1, 2021 | March 31, 2026 | ZACK, JEROME A. | reporter.nih.gov |
| SCGE Disease Models Studies Supplement: Development of LNP-mediated based editing to treat Leber Congenital Amaurosis (LCA) for vision restoration in mouse model | NIH | National Center for Advancing Translational Sciences | 2021 to 2022 | $3,783,475 | September 18, 2018 | July 31, 2023 | CHEN, ZHENG-YI | reporter.nih.gov |
| Activated NK CAR Cells to Cure HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,780,061 | April 2, 2021 | March 31, 2027 | SKINNER, PAMELA J | reporter.nih.gov |
| Human natural killer cells: Advancing biology and clinical applications | NIH | National Cancer Institute | 2021 to 2025 | $3,769,374 | July 21, 2017 | June 30, 2032 | CALIGIURI, MICHAEL A | reporter.nih.gov |
| Novel therapeutic gene editing to induce fetal hemoglobin for sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $3,710,340 | September 1, 2023 | August 31, 2028 | WEISS, MITCHELL J | reporter.nih.gov |
| Translational Gene Therapy for CNGB1 Retinitis Pigmentosa | NIH | National Eye Institute | 2021 to 2022 | $3,709,328 | April 1, 2018 | July 31, 2025 | PETERSEN-JONES, SIMON | reporter.nih.gov |
| Optimizing Hematopoietic Stem Cell Transplantation For The Treatment Of Hematological Malignancies | NIH | National Cancer Institute | 2021 to 2025 | $3,687,540 | September 7, 2017 | June 30, 2032 | DIPERSIO, JOHN F. | reporter.nih.gov |
| Gene Transfer and NMR Studies in Alpha-Mannosidosis Brain | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,684,704 | September 3, 2002 | July 31, 2026 | WOLFE, JOHN H | reporter.nih.gov |
| Enhancing immune regulation in gene therapy for hemophilia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,664,714 | July 1, 2016 | June 30, 2029 | HERZOG, ROLAND W. | reporter.nih.gov |
| NGTC - UCL | NIH | National Cancer Institute | 2022 to 2024 | $3,627,871 | June 1, 2024 | May 31, 2025 | PULE, MARTIN | reporter.nih.gov |
| Targeting CNS reservoirs with CAR/CXCR5 T cells for the long-term remission of HIV | NIH | National Institute of Mental Health | 2022 to 2025 | $3,610,311 | August 5, 2022 | May 31, 2027 | SKINNER, PAMELA J | reporter.nih.gov |
| Optimizing AAV delivery of bNAbs for HIV prevention | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,607,044 | November 24, 2021 | October 31, 2026 | GARDNER, MATTHEW RYAN | reporter.nih.gov |
| UC Irvine Center for the production and distribution of cell-type-specific viral targeting reagents | NIH | National Institute of Mental Health | 2023 to 2025 | $3,599,166 | July 15, 2023 | April 30, 2026 | XU, XIANGMIN | reporter.nih.gov |
| PP2A Anchoring Disruptor Therapy in Heart Failure | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $3,544,947 | September 1, 2021 | August 31, 2025 | CIVIDINI, FEDERICO | reporter.nih.gov |
| AAV capsid engineering for enhancing gene transfer | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,541,347 | March 1, 2015 | April 30, 2030 | KAY, MARK A | reporter.nih.gov |
| Synthetic circuit technologies for precision control and signal processing in mammalian cells | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2025 | $3,539,495 | May 1, 2020 | April 30, 2028 | KHALIL, AHMAD SAMIR | reporter.nih.gov |
| Acute/chronic limitations to transcriptional RNAi therapies for infectious and other liver diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,515,317 | August 1, 2006 | July 31, 2026 | KAY, MARK A | reporter.nih.gov |
| Structural and Mechanistic basis for RNA Silencing | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,507,599 | August 1, 2018 | July 31, 2028 | MACRAE, IAN JOHN | reporter.nih.gov |
| Understanding and manipulating programmed cell death (PCD) pathways to facilitate lymphoid tumor killing by CAR T cells | NIH | National Cancer Institute | 2021 to 2025 | $3,469,484 | January 7, 2021 | December 31, 2025 | MAUS, MARCELA VALDERRAMA | reporter.nih.gov |
| A phase I trial of AdKCNH2-G628S gene therapy for post-op atrial fibrillation | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $3,447,560 | September 15, 2021 | August 31, 2024 | DONAHUE, J KEVIN | reporter.nih.gov |
| Viral Gene Therapy for Menkes Disease | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $3,444,962 | September 1, 2023 | June 30, 2027 | KALER, STEPHEN GERARD | reporter.nih.gov |
| TLE transcription cofactors in anti-viral and anti-tumor immunity | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,436,588 | July 18, 2025 | June 30, 2029 | XUE, HAI-HUI | reporter.nih.gov |
| CAR-T cell treatment of CNS Autoimmunity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,403,175 | June 13, 2022 | May 31, 2027 | WU, GREGORY | reporter.nih.gov |
| Gene therapy for SCID-X1 with low dose busulfan and a SIN-lentiviral vector | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,369,470 | July 7, 2016 | December 31, 2029 | WILLIAMS, DAVID A | reporter.nih.gov |
| Defining short RNA therapeutics that combat TDP-43 proteinopathy connected to AD and ADRDs. | NIH | National Institute on Aging | 2025 | $3,360,074 | September 15, 2025 | August 31, 2029 | SHORTER, JAMES | reporter.nih.gov |
| Dystrophin Replacement | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $3,349,499 | April 1, 1991 | April 30, 2026 | CHAMBERLAIN, JEFFREY S | reporter.nih.gov |
| Clinically Translatable MRI Reporter Genes and Imaging Methods with Ultra-High Specificity and Sensitivity | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2025 | $3,332,874 | April 1, 2021 | December 31, 2028 | FARRAR, CHRISTIAN T | reporter.nih.gov |
| Toward development of senolytic CAR T cells | NIH | National Institute on Aging | 2025 | $3,326,400 | May 15, 2020 | August 31, 2029 | LOWE, SCOTT W. | reporter.nih.gov |
| Engineering 2nd generation 5MCARs to monitor and treat Type-I Diabetes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $3,325,791 | April 1, 2022 | March 31, 2027 | KUHNS, MICHAEL S | reporter.nih.gov |
| The impact of interstitial fluid flow on CAR T cell trafficking, distribution, and efficacy | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,320,824 | June 15, 2021 | March 31, 2027 | MUNSON, JENNIFER M | reporter.nih.gov |
| Engineering AAV for safe and efficient gene delivery to the human retina | NIH | National Eye Institute | 2021 to 2025 | $3,303,996 | June 1, 2014 | June 30, 2029 | BOYE, SHANNON ELIZABETH | reporter.nih.gov |
| Developing Safe and Effective GD2-CAR T Cell Therapy for Diffuse Midline Gliomas | NIH | National Cancer Institute | 2021 to 2025 | $3,294,656 | August 6, 2021 | July 31, 2026 | MACKALL, CRYSTAL | reporter.nih.gov |
| Stable therapy in Pompe disease through genome editing | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $3,274,213 | August 1, 2021 | July 31, 2026 | KOEBERL, DWIGHT D | reporter.nih.gov |
| Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer | NIH | National Cancer Institute | 2022 to 2025 | $3,252,105 | April 1, 2022 | August 31, 2027 | POWELL, DANIEL J. | reporter.nih.gov |
| AAV-delivered HIV inhibitors for SHIV therapy | NIH | National Institute on Drug Abuse | 2022 to 2025 | $3,245,455 | August 15, 2022 | May 31, 2027 | GARDNER, MATTHEW RYAN | reporter.nih.gov |
| Multi-Targeting Oligonucleotide Therapeutics for Familial and Sporadic Amyotrophic Lateral Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,236,744 | May 15, 2019 | May 31, 2029 | WATTS, JONATHAN K | reporter.nih.gov |
| Immunomodulation in AAV gene therapy | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,192,404 | August 21, 2025 | July 31, 2029 | ASOKAN, ARAVIND | reporter.nih.gov |
| Targeted Gene Delivery Systems Treating Lung Diseases | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,172,072 | June 15, 2022 | May 31, 2026 | TIRRELL, MATTHEW | reporter.nih.gov |
| Development of peptide nucleic acid antibiotics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,164,488 | February 10, 2021 | January 31, 2025 | ARYA, DEV PRIYA | reporter.nih.gov |
| IND-enabling studies of non-immunogenic gene therapy for ultra-rare DMD patients excluded from dystrophin trials | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $3,161,261 | August 1, 2024 | July 31, 2027 | STEDMAN, HANSELL H | reporter.nih.gov |
| Immunotherapy via engineered therapeutic programs in tumors using RNA | NIH | National Cancer Institute | 2021 to 2025 | $3,154,064 | September 20, 2021 | August 31, 2027 | WEISS, RON | reporter.nih.gov |
| A Massive Library of AAVs to Target Transcriptionally-Defined Primate Cell Types | NIH | National Institute of Mental Health | 2023 to 2024 | $3,125,402 | September 1, 2019 | August 31, 2025 | STAUFFER, WILLIAM RICHARD | reporter.nih.gov |
| A Novel RNA Therapeutics Platform to Treat Facioscapulohumeral Muscular Dystrophy and other Neuromuscular Disorders | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,123,687 | September 20, 2021 | August 31, 2027 | SALEH, ANTHONY D | reporter.nih.gov |
| PROTECT (Harnessing PROTEin degradation for Advanced Childhood Tumors) | NIH | National Cancer Institute | 2024 to 2025 | $3,108,431 | May 1, 2024 | April 30, 2026 | STEGMAIER, KIMBERLY | reporter.nih.gov |
| Engineering T cells to Promote Islet Transplant | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $3,102,316 | April 1, 2022 | March 31, 2027 | RILEY, JAMES L. | reporter.nih.gov |
| Engineered Immune Cells for T1D | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $3,097,818 | April 1, 2022 | March 31, 2026 | MEYER, EVERETT | reporter.nih.gov |
| Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors | NIH | National Center for Advancing Translational Sciences | 2021 to 2022 | $3,091,036 | September 18, 2018 | July 31, 2024 | SONTHEIMER, ERIK J. | reporter.nih.gov |
| Vascular Targeting of Nanocarriers for RNA | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,088,329 | February 5, 2021 | January 31, 2026 | MUZYKANTOV, VLADIMIR R | reporter.nih.gov |
| Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,081,124 | January 16, 2020 | December 31, 2024 | YANG, OTTO O | reporter.nih.gov |
| CD28-KITv CAR T cells with PD-1 dominant negative receptor | NIH | National Cancer Institute | 2024 to 2025 | $3,061,861 | March 1, 2024 | February 28, 2026 | ADUSUMILLI, PRASAD S. | reporter.nih.gov |
| Adeno-Associated Virus Gene Therapy Vectors: Molecular Interactions on Cell Entry | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,051,473 | August 1, 2017 | July 31, 2028 | CHAPMAN, MICHAEL S. | reporter.nih.gov |
| Advancing programmable RNA-targeting tools for research and therapeutics | NIH | National Human Genome Research Institute | 2021 to 2024 | $3,040,774 | August 17, 2017 | June 30, 2025 | ZHANG, FENG | reporter.nih.gov |
| Controllable solid tumor immunotherapy based on a wireless thermos-activator | NIH | National Cancer Institute | 2025 | $3,036,844 | August 11, 2025 | July 31, 2029 | WANG, YINGXIAO | reporter.nih.gov |
| In Situ Albumin Binding siRNAs for Triple Negative Breast Cancer Tumor Penetration and Molecularly Targeted Therapy | NIH | National Cancer Institute | 2021 to 2025 | $3,035,458 | July 5, 2021 | June 30, 2027 | DUVALL, CRAIG LEWIS | reporter.nih.gov |
| Providing ethical guidance for the development of individualized genomic medicine as rare as n-of-1 | NIH | National Human Genome Research Institute | 2022 to 2025 | $3,020,238 | September 1, 2022 | June 30, 2026 | YU, TIMOTHY WEI-WEN | reporter.nih.gov |
| Trial Readiness and Endpoint Assessment in LGMDR1 (TREATing-LGMDR1) | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $3,017,334 | April 15, 2023 | March 31, 2028 | JOHNSON, NICHOLAS ELWOOD | reporter.nih.gov |
| Novel model systems for the study of cone disorders and other heritable retinal diseases | NIH | National Eye Institute | 2021 to 2023 | $3,008,070 | September 30, 2018 | August 31, 2024 | ROGERS, JEFFREY A. | reporter.nih.gov |
| Enhancer AAV toolbox for cell classes and subclasses in the brains of mouse, macaque and marmoset. | NIH | National Institute of Mental Health | 2025 | $3,007,397 | May 1, 2025 | February 28, 2030 | TASIC, BOSILJKA | reporter.nih.gov |
| Advanced generation infection-proof anti-HIV CAR-T with YY1 RNAi to block T cell exhaustion in NHP model | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $3,000,000 | April 17, 2020 | July 31, 2025 | JUNGHANS, RICHARD P | reporter.nih.gov |
| Manufacturing RNA-based CAR T cells to combat autoantibody-associated autoimmune disorders (AAAD) | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $2,992,236 | June 7, 2024 | May 31, 2026 | STEWART, CHARLES ANDREW | reporter.nih.gov |
| Development of Gene Replacement Therapy for Sanfilippo Syndrome Type C | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $2,990,505 | September 19, 2022 | August 31, 2025 | SINGAMSETTY, SRIKANTH | reporter.nih.gov |
| Genetically-engineered stem cells for self-regulating arthritis therapy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $2,983,611 | April 1, 2022 | March 31, 2027 | GUILAK, FARSHID | reporter.nih.gov |
| Screening for rAAV transduction enhancers | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,974,481 | January 27, 2017 | January 31, 2025 | BOWLIN, TERRY L. | reporter.nih.gov |
| Immune tolerance induction by AAV-FVIII gene therapy for canine hemophilia A with inhibitors | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,952,138 | September 1, 2021 | June 30, 2026 | SAMELSON-JONES, BEN J | reporter.nih.gov |
| Develop combinatorial non-viral and viral CRISPR delivery for lung diseases | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $2,938,558 | September 10, 2018 | August 31, 2024 | GAO, GUANGPING | reporter.nih.gov |
| Precise targeting of T1D specific T cells using CAR and peptide-MHC chimeric antigen ligands | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,937,157 | May 15, 2022 | April 30, 2027 | WONG, WILSON | reporter.nih.gov |
| Scaled identification of receptor-targeted AAVs for potent and cell type-specific transgene delivery | NIH | National Institute of Mental Health | 2025 | $2,935,208 | September 1, 2025 | May 31, 2030 | GRADINARU, VIVIANA | reporter.nih.gov |
| Clinical Evaluation of Chlorotoxin-redirected Chimeric Antigen Receptor (CAR) T cells for Treatment of Glioblastoma | NIH | National Cancer Institute | 2021 to 2024 | $2,929,456 | August 1, 2020 | April 30, 2026 | BROWN, CHRISTINE | reporter.nih.gov |
| Enhancing B7-H3-CAR T cell therapy for pediatric solid tumors | NIH | National Cancer Institute | 2022 to 2025 | $2,924,883 | March 1, 2022 | February 28, 2027 | DERENZO, CHRISTOPHER | reporter.nih.gov |
| Towards Safer and More Effective CART Cell Therapy Through the Modulation of Myeloid Cytokines | NIH | National Cancer Institute | 2022 to 2025 | $2,917,317 | December 9, 2021 | November 30, 2026 | KENDERIAN, SAAD J. | reporter.nih.gov |
| Dual-targeted DOTA CAR T cells with image-guided monitoring for solid tumor treatment | NIH | National Cancer Institute | 2024 to 2025 | $2,906,182 | September 9, 2024 | August 31, 2026 | POWELL, DANIEL J. | reporter.nih.gov |
| Gene Therapy in Hutchinson-Gilford Progeria Syndrome | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,900,379 | March 15, 2022 | February 28, 2027 | BROWN, JONATHAN DAVID | reporter.nih.gov |
| Retinal disease models for translational photoreceptor replacement | NIH | National Eye Institute | 2021 to 2022 | $2,898,123 | September 30, 2018 | May 31, 2025 | WOLFE, JOHN H | reporter.nih.gov |
| CRISPR-Cas13 gene therapy and RNA editing for Facioscapulohumeral muscular dystrophy (FSHD) | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $2,896,188 | August 15, 2021 | July 31, 2026 | HARPER, SCOTT Q | reporter.nih.gov |
| Development of a SYF2 antisense oligonucleotide treatment for ALS and FTD | NIH | National Institute on Aging | 2023 to 2024 | $2,894,619 | August 1, 2023 | July 31, 2025 | ALWORTH, SAMUEL V | reporter.nih.gov |
| Intratumor co-delivery of DNA and RNA to relieve cancer pain | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2025 | $2,893,104 | January 8, 2021 | December 31, 2026 | SCHMIDT, BRIAN L | reporter.nih.gov |
| Overcoming metastatic spread of osteosarcoma with RNA loaded nanoparticles | NIH | National Cancer Institute | 2022 to 2025 | $2,889,170 | September 1, 2022 | August 31, 2027 | SAYOUR, ELIAS | reporter.nih.gov |
| Mechanistic Studies of AAP and Capsid Assembly of AAV Vectors | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,884,680 | December 1, 2019 | November 30, 2025 | NAKAI, HIROYUKI | reporter.nih.gov |
| Genetic Repair of Familial Hypercholesterolemia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,883,128 | December 20, 2016 | March 31, 2027 | LAGOR, WILLIAM RAYMOND | reporter.nih.gov |
| Synthetic circuits that drive infiltration of therapeutic T cells into immunologically cold tumors | NIH | National Cancer Institute | 2021 to 2025 | $2,872,622 | September 10, 2021 | August 31, 2026 | LIM, WENDELL A | reporter.nih.gov |
| New and Disruptive Therapeutic Approaches to Target Fundamental Molecular Mechanisms Underlying Atrial Fibrillation | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $2,860,799 | January 20, 2022 | July 8, 2024 | ARORA, RISHI | reporter.nih.gov |
| Translational Research for Retinal Degeneration Therapies | NIH | National Eye Institute | 2021 to 2024 | $2,827,259 | September 30, 2007 | August 31, 2025 | BELTRAN, WILLIAM A. | reporter.nih.gov |
| Developing gene therapy strategies to treat alpha thalassemia | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,821,947 | January 1, 2022 | December 31, 2025 | MACKENZIE, TIPPI | reporter.nih.gov |
| In vivo engineering of B cells for the secretion of HIV broadly neutralizing antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,818,132 | December 3, 2021 | November 30, 2026 | VOSS, JAMES EVEN | reporter.nih.gov |
| Genome editing of human pancreatic islets to withstand ischemic injuries and promote immune evasion | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,817,305 | July 1, 2022 | April 30, 2027 | TANG, QIZHI | reporter.nih.gov |
| Development of gene editing based therapy for cardiovascular diseases | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,813,308 | July 1, 2021 | June 30, 2025 | CHEN, YUQING EUGENE | reporter.nih.gov |
| AAV-mediated delivery of eCD4-Ig for prevention and treatment of perinatal HIV infection | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $2,809,667 | August 7, 2020 | May 31, 2026 | MARTINS, MAURICIO DE AGUIAR | reporter.nih.gov |
| Hepatic gene transfer for the treatment of hemophilia B and other genetic diseases | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,797,035 | September 1, 2000 | December 31, 2027 | KAY, MARK A | reporter.nih.gov |
| Targeted lipid nanoparticles for gene therapeutics delivery approach to eradicating HIV reservoirs | NIH | National Institute of Mental Health | 2021 to 2025 | $2,789,702 | September 23, 2019 | February 28, 2030 | GENDELMAN, HOWARD E | reporter.nih.gov |
| Accelerate cellular immunotherapy development for treatment of life-threatening childhood disorders | NIH | National Center for Advancing Translational Sciences | 2021 to 2022 | $2,786,444 | August 1, 2018 | July 31, 2024 | PARK, JULIE R | reporter.nih.gov |
| A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T cells Targeting TAG72 in Patients with Recurrent Epithelial Ovarian Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,785,861 | September 1, 2022 | June 30, 2027 | RODRIGUEZ-RODRIGUEZ, LORNA | reporter.nih.gov |
| Modeling and Therapeutic Approaches for Genetic Vasculopathies | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,784,876 | September 20, 2022 | July 31, 2027 | MUSOLINO, PATRICIA L | reporter.nih.gov |
| Next Generation GPC2-CARs for Medulloblastoma | NIH | National Cancer Institute | 2024 to 2025 | $2,781,440 | September 13, 2024 | August 31, 2026 | MACKALL, CRYSTAL | reporter.nih.gov |
| Intraosseous delivery of lentiviral vectors for hemophilia A gene therapy | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,777,901 | August 15, 2016 | June 30, 2026 | MIAO, CAROL H | reporter.nih.gov |
| Neurocognitive and Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell Therapy: A Controlled Comparison | NIH | National Cancer Institute | 2022 to 2025 | $2,766,745 | July 1, 2022 | June 30, 2027 | JIM, HEATHER S.L. | reporter.nih.gov |
| Immunoglobulin Replacement Therapy and Infectious Complications After CD19-Targeted CAR-T-Cell Therapy | NIH | National Cancer Institute | 2023 to 2025 | $2,766,158 | September 1, 2023 | August 31, 2028 | HILL, JOSHUA AIDEN | reporter.nih.gov |
| CAR T cells targeting mesothelin and secreting bispecific antibodies targeting fibroblasts in pancreatic cancer | NIH | National Cancer Institute | 2023 to 2024 | $2,756,416 | August 9, 2023 | July 31, 2025 | MAUS, MARCELA VALDERRAMA | reporter.nih.gov |
| Retinal-adhesive thermoresponsive gel for AAV-mediated gene delivery to the outer retina | NIH | National Eye Institute | 2022 to 2025 | $2,749,546 | September 30, 2022 | July 31, 2027 | SAHEL, JOSE-ALAIN | reporter.nih.gov |
| Next Generation Gene Therapy for Refractory Pain | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,745,930 | February 1, 2022 | January 31, 2027 | RENTHAL, WILLIAM RUSSELL | reporter.nih.gov |
| Long-Acting RNAi Therapy for Atherosclerosis and Insulin Resistance | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,745,822 | July 1, 2021 | June 30, 2026 | SHI, JINJUN | reporter.nih.gov |
| In vivo HSC gene therapy using a multi-modular HDAd vector for HIV cure | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,743,808 | January 10, 2023 | December 31, 2027 | LIEBER, ANDRE MICHAEL | reporter.nih.gov |
| In Vivo Gene Editing of B cells with NICE-AAV Vectors | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,735,041 | December 16, 2021 | November 30, 2026 | PETERSON, CHRISTOPHER W | reporter.nih.gov |
| Systemic RNA Delivery to Tumors | NIH | National Cancer Institute | 2021 to 2025 | $2,731,905 | December 21, 2015 | June 30, 2027 | SHI, JINJUN | reporter.nih.gov |
| Efficacy and immune effects of anakinra prophylaxis for neurologic toxicity and cytokine release syndrome in patients with lymphoma receiving axicabtagene ciloleucel | NIH | National Cancer Institute | 2021 to 2024 | $2,726,050 | September 1, 2020 | May 31, 2025 | MAUS, MARCELA VALDERRAMA | reporter.nih.gov |
| Development of microRNA (miR)-based cell-targeted polymeric nanoparticles for myeloma therapy | NIH | National Cancer Institute | 2021 to 2025 | $2,723,368 | February 9, 2021 | March 31, 2027 | CARRASCO, RUBEN D | reporter.nih.gov |
| HORMAD-specific TGF-beta resistant memory T cells for treatment of patients with Gastro-esophageal Cancer | NIH | National Cancer Institute | 2023 to 2024 | $2,717,589 | September 19, 2023 | August 31, 2025 | YEE, CASSIAN | reporter.nih.gov |
| Next generation T cell therapies for mutant KRAS solid tumors | NIH | National Cancer Institute | 2023 to 2024 | $2,717,473 | September 1, 2023 | August 31, 2025 | CARRENO, BEATRIZ M. | reporter.nih.gov |
| [18F]4FN PET Imaging of Innate Immunity Activation During Immunotherapy-Induced Adverse Events | NIH | National Cancer Institute | 2022 to 2025 | $2,714,023 | September 1, 2022 | August 31, 2027 | PIWNICA-WORMS, DAVID | reporter.nih.gov |
| Expanding the Chemical Diversity of Therapeutic Oligonucleotides | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,703,592 | September 25, 2017 | March 31, 2028 | KHVOROVA, ANASTASIA | reporter.nih.gov |
| Gene therapy for glycogen storage disease type III | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $2,697,948 | April 1, 2022 | March 31, 2027 | SUN, BAODONG | reporter.nih.gov |
| Controlling complement to unleash nanomedicine for acute critical illnesses | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,697,599 | February 1, 2022 | January 31, 2026 | BRENNER, JACOB | reporter.nih.gov |
| Enhancing The Value of Pigs for Agriculture and Biomedical Applications By Using Novel Genome Editing Strategies | NIH | Office of the Director, National Institutes of Health | 2023 to 2025 | $2,687,862 | July 1, 2023 | June 30, 2027 | LEE, KIHO | reporter.nih.gov |
| Defining the therapeutic efficacy, tolerogenic potential, and genotoxicity of liver-targeted AAV gene therapy for hemophilia A | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,682,494 | September 15, 2022 | June 30, 2027 | ALMEIDA-PORADA, GRACA DUARTE | reporter.nih.gov |
| In vivo CRISPR engineering of B cells to produce anti-HIV broadly neutralizing antibodies using novel nanoparticles | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,680,549 | June 8, 2022 | April 1, 2025 | ADAIR, JENNIFER EILEEN | reporter.nih.gov |
| Development of an UNC13A antisense oligonucleotide treatment for ALS and FTD | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $2,670,896 | August 1, 2023 | July 31, 2025 | CHANG, WEN-HSUAN | reporter.nih.gov |
| Novel AAVs Engineered for Efficient and Noninvasive Cross-Species Gene Editing Throughout the Central Nervous System | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $2,664,985 | September 30, 2018 | July 31, 2025 | DEVERMAN, BENJAMIN E | reporter.nih.gov |
| BAFF-R CAR T cell therapy for ALL | NIH | National Cancer Institute | 2022 to 2025 | $2,663,058 | April 18, 2022 | March 31, 2027 | WANG, XIULI | reporter.nih.gov |
| A Human cDNA Library for Functional Gene Replacement in Drosophila | NIH | Office of the Director, National Institutes of Health | 2021 to 2023 | $2,661,921 | June 1, 2016 | May 31, 2025 | BELLEN, HUGO J | reporter.nih.gov |
| A high-performance and versatile technology for precision microbiome engineering | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2024 | $2,652,300 | September 1, 2021 | May 31, 2026 | WANG, HARRIS H | reporter.nih.gov |
| Structural studies of viral replication and invasion | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $2,649,373 | July 1, 2016 | December 31, 2026 | AIHARA, HIDEKI | reporter.nih.gov |
| Supplement: Stalled capillary flow affects protein clearance by modulating interstitial fluid flow | NIH | National Institute on Aging | 2021 to 2022 | $2,646,437 | May 15, 2015 | April 30, 2024 | SCHAFFER, CHRIS B | reporter.nih.gov |
| GENE THERAPY RESOURCE PROGRAM (GTRP),TASK AREA A: CORE ADMINISTRATIVE TASKS | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $2,642,623 | December 19, 2023 | June 30, 2024 | JOHNSTON, JULIE | reporter.nih.gov |
| Translation of a novel combination therapy approach for non-Hodgkin lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $2,620,855 | September 1, 2022 | August 31, 2027 | NAIK, SHRUTHI | reporter.nih.gov |
| Image-guided cancer therapy using heat activatable CAR T cells | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $2,619,925 | September 15, 2022 | June 30, 2027 | EMELIANOV, STANISLAV Y | reporter.nih.gov |
| In Vivo Hematopoietic Stem Cell Gene Therapy of Beta-Thalassemia and Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,618,613 | June 1, 2016 | July 31, 2025 | LIEBER, ANDRE MICHAEL | reporter.nih.gov |
| Development of 211Astatine-Conjugated Anti-CD45 Antibody-Based Conditioning for Hematopoietic Stem Cell Gene Therapy and Editing | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,608,434 | May 15, 2020 | April 30, 2026 | WALTER, ROLAND BRUNO | reporter.nih.gov |
| Translational Nonhuman Primate Regenerative Medicine and Gene Therapy/Genome Editing Resource Program | NIH | Office of the Director, National Institutes of Health | 2023 to 2025 | $2,607,543 | December 1, 2022 | November 30, 2026 | TARANTAL, ALICE F | reporter.nih.gov |
| Development of Gene Therapy for Hereditary Deafness using Rational Protein Engineering | NIH | National Institute on Deafness and Other Communication Disorders | 2022 to 2025 | $2,600,046 | June 17, 2022 | May 31, 2027 | INDZHYKULIAN, ARTUR | reporter.nih.gov |
| Gene Therapy Consortium (GTC) for Gene-Based Clinical Trials Conducted within NeuroNEXT | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $2,596,654 | August 15, 2025 | August 14, 2026 | CUDKOWICZ, MERIT E | reporter.nih.gov |
| Molecular mechanisms of T cell responses to a clonal neoantigen resulting from a mutated driver oncogene. | NIH | National Cancer Institute | 2021 to 2025 | $2,596,206 | April 1, 2021 | March 31, 2026 | KLEBANOFF, CHRISTOPHER AUSTIN | reporter.nih.gov |
| eCD4-Mediated Control of SIV Infection in the Brain | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $2,593,389 | June 1, 2023 | May 31, 2028 | FARZAN, MICHAEL R. | reporter.nih.gov |
| Overcoming pre-existing immunity to AAV to enhance AAV-based HIV immunotherapies | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,592,792 | December 5, 2022 | November 30, 2027 | MARTINS, MAURICIO A | reporter.nih.gov |
| Personalization and Failure Testing of Dual Switch Gene Drives in Lung Cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,591,489 | September 10, 2021 | August 31, 2026 | PRITCHARD, JUSTIN | reporter.nih.gov |
| In vivo delivery of engineered tRNAs for suppression of nonsense mutations | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,591,222 | April 10, 2021 | March 31, 2026 | LUECK, JOHN D. | reporter.nih.gov |
| Development of an IOP-lowering gene therapy treatment for glaucoma | NIH | National Eye Institute | 2022 to 2025 | $2,587,720 | June 1, 2022 | May 31, 2027 | LIPINSKI, DANIEL MARK | reporter.nih.gov |
| Rectifying splicing mutations in blood disorders by gene editing | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,584,045 | December 20, 2019 | November 30, 2023 | BAUER, DANIEL EVAN | reporter.nih.gov |
| Optimizing Dual-Targeted and Dual-Armored CAR T Cells for Small Cell LungCancer | NIH | National Cancer Institute | 2022 to 2025 | $2,583,947 | April 1, 2021 | March 31, 2027 | BRENTJENS, RENIER JOSEPH | reporter.nih.gov |
| Targeted genetic engineering of B cells to induce protective antibody responses to viral pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,577,835 | July 5, 2022 | June 30, 2027 | ADAIR, JENNIFER EILEEN | reporter.nih.gov |
| Cell type selective viral tools to interrogate and correct non-human primate and human brain circuitry | NIH | National Institute of Mental Health | 2021 to 2022 | $2,577,166 | September 1, 2020 | February 29, 2024 | TING, JONATHAN T | reporter.nih.gov |
| Phase I therapeutic testing of viral-vectored vaccines that shift CD8+ T cell immunodominance to conserved regions of HIV-1 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,576,704 | July 14, 2022 | June 30, 2025 | GOONETILLEKE, NILU | reporter.nih.gov |
| Delivering inhalable nanoparticles containing AI-optimized CFTR mRNA with a novel microfluidic device for treatment of CF | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,575,533 | April 1, 2019 | April 30, 2029 | SAHAY, GAURAV | reporter.nih.gov |
| COATs: Collagen-mimetic peptide and therapeutic gene-modified collagens for cell-mediated healing of diabetic foot ulcers | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,574,620 | July 30, 2021 | May 31, 2027 | SULLIVAN, MILLICENT O | reporter.nih.gov |
| Persistent STAT5 signaling in polyfunctional CD4 T cells and its application in adoptive T cell therapy | NIH | National Cancer Institute | 2021 to 2025 | $2,572,103 | July 1, 2021 | June 30, 2027 | ZHOU, GANG | reporter.nih.gov |
| Enhancement, mapping, and validation of viral vectors for primate optogenetics | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,571,104 | January 15, 2022 | December 31, 2026 | SOMMER, MARC A | reporter.nih.gov |
| Mito-Targeted AAV to treat Leber Hereditary Optic Neuropathy caused by ND4 mutations | NIH | National Eye Institute | 2021 to 2023 | $2,570,468 | March 1, 2019 | December 31, 2025 | PORCIATTI, VITTORIO | reporter.nih.gov |
| Defining and Controlling Protein-RNA interactions in editing and interference pathways | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,564,404 | May 1, 2021 | June 14, 2026 | BEAL, PETER A. | reporter.nih.gov |
| Vectored HIV Immunotherapy via in vivo B cell editing | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,561,518 | January 1, 2024 | December 31, 2028 | CURIEL, DAVID TERRY | reporter.nih.gov |
| Developing Durable, Env-Boosted CAR T Cells for HIV Cure | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,557,695 | November 2, 2022 | October 31, 2027 | PETERSON, CHRISTOPHER W | reporter.nih.gov |
| Preserving Genome Integrity In AAV-Mediated Gene Therapy | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,554,264 | February 1, 2022 | January 31, 2027 | SABATINO, DENISE E | reporter.nih.gov |
| Vascular networks genetically engineered for protein drug delivery | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,552,882 | August 15, 2015 | April 30, 2026 | MELERO-MARTIN, JUAN M | reporter.nih.gov |
| Spinal Subpial Gene Delivery for Treatment of Amyotrophic Lateral Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,547,168 | September 28, 2022 | July 31, 2027 | MARSALA, MARTIN | reporter.nih.gov |
| Mechanistic analysis and allellic genome editing of iPSC-derived dominant LCA model | NIH | National Eye Institute | 2021 to 2025 | $2,545,050 | January 1, 2021 | November 30, 2025 | ULLIAN, ERIK M | reporter.nih.gov |
| Development of a universal gene therapy for hemophilia A or B with or without inhibitors | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $2,542,236 | April 10, 2024 | March 31, 2027 | MARGARITIS, PARIS | reporter.nih.gov |
| Precise tumor targeting with logic CAR circuits | NIH | National Cancer Institute | 2021 to 2025 | $2,539,139 | September 17, 2021 | August 31, 2026 | WONG, WILSON | reporter.nih.gov |
| Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy | NIH | National Cancer Institute | 2022 to 2025 | $2,526,052 | September 9, 2022 | August 31, 2027 | FINLEY, STACEY DELERIA | reporter.nih.gov |
| Developing gene editing platforms for retinal degeneration. | NIH | National Eye Institute | 2022 to 2025 | $2,519,176 | September 30, 2022 | June 30, 2027 | SAHAY, GAURAV | reporter.nih.gov |
| Targeting B7-H3 in ovarian cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,515,188 | February 1, 2021 | January 31, 2027 | DOTTI, GIANPIETRO | reporter.nih.gov |
| Real-Time Tracking of Gene Therapy by Bioactivated MR contrast Probes | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,508,603 | September 1, 2020 | May 31, 2026 | MEADE, THOMAS J | reporter.nih.gov |
| Gene Therapy for Alpha 1-Antitrypsin Deficiency | NIH | National Heart, Lung, and Blood Institute | 2025 | $2,505,334 | May 15, 2024 | April 30, 2028 | CRYSTAL, RONALD G | reporter.nih.gov |
| Editing Alveolar Progenitor Cells for Correction of Monogenic Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $2,504,499 | September 23, 2016 | May 31, 2025 | WHITSETT, JEFFREY A | reporter.nih.gov |
| Scalable Development of Custom Genome Editing Technologies | NIH | National Cancer Institute | 2022 to 2025 | $2,502,000 | September 20, 2022 | August 31, 2027 | KLEINSTIVER, BENJAMIN PETER | reporter.nih.gov |
| Intracerebroventricular (ICV) Administration of CD19-Targeting Chimeric Antigen Receptor (CAR) T cells for Treatment of Primary Central Nervous System Lymphoma | NIH | National Cancer Institute | 2022 to 2025 | $2,499,820 | September 9, 2022 | August 31, 2028 | WANG, XIULI | reporter.nih.gov |
| Therapeutic strategies for microsatellite expansion diseases using RNA targeting | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,491,089 | September 22, 2017 | November 30, 2027 | YEO, EUGENE WEI-MING | reporter.nih.gov |
| Developing macrophage reprogramming mRNA nanocarriers for initial clinical testing | NIH | National Cancer Institute | 2021 to 2024 | $2,491,070 | April 1, 2022 | July 31, 2025 | STEPHAN, MATTHIAS | reporter.nih.gov |
| IL-15 and -21 armored GPC3-specific CAR T cells for children with solid tumors | NIH | National Cancer Institute | 2022 to 2025 | $2,490,304 | January 17, 2022 | October 31, 2025 | HECZEY, ANDRAS A. | reporter.nih.gov |
| Gene therapy for disorders of the extracellular matrix | NIH | National Institute of Neurological Disorders and Stroke | 2023 | $2,481,348 | April 1, 2023 | March 31, 2026 | GOULD, DOUGLAS | reporter.nih.gov |
| Tailoring CAR T cell therapy for Hodgkin Lymphoma | NIH | National Cancer Institute | 2021 to 2024 | $2,475,444 | July 1, 2020 | June 30, 2026 | SAVOLDO, BARBARA | reporter.nih.gov |
| Molecular brush-conjugated antisense oligonucleotide as a pan-KRAS depletion agent | NIH | National Cancer Institute | 2022 to 2024 | $2,473,054 | September 1, 2022 | August 31, 2025 | ZHANG, KE | reporter.nih.gov |
| Genetic-engineered control of the immunogeneic state of vascular composite allografts during preservation | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2025 | $2,471,566 | July 1, 2021 | March 31, 2029 | UYGUN, KORKUT | reporter.nih.gov |
| Cell-Selective Therapies for Coronary Artery Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,469,740 | July 15, 2015 | December 31, 2026 | TOTARY-JAIN, HANA | reporter.nih.gov |
| Mechanism of transplanted neonatal cardiac progenitor cells to repair ischemic myocardium | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,462,741 | April 20, 2014 | August 31, 2025 | SCHUMACKER, PAUL T | reporter.nih.gov |
| Mechanistic factors limiting utility of adenovirus vectors for treatment of neopla | NIH | National Cancer Institute | 2022 to 2025 | $2,454,583 | May 5, 2022 | April 30, 2027 | SHAYAKHMETOV, DMITRY | reporter.nih.gov |
| In vivo transformation of chimeric antigen receptor B cells for a functional cure of HIV | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,449,124 | July 7, 2023 | June 30, 2028 | FARZAN, MICHAEL R. | reporter.nih.gov |
| Tuning CAR-T cell function | NIH | National Cancer Institute | 2021 to 2025 | $2,440,223 | January 1, 2021 | December 31, 2026 | DOTTI, GIANPIETRO | reporter.nih.gov |
| Translating post-infarct ventricular tachycardia mechanisms into a therapy | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,437,249 | January 9, 2023 | December 31, 2026 | DONAHUE, J KEVIN | reporter.nih.gov |
| Stem cells for therapeutics discovery in genetic blood disorders | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $2,429,809 | September 23, 2016 | May 31, 2025 | DALEY, GEORGE Q | reporter.nih.gov |
| Targeting Fibroblast Discoidin Domain Receptor 2 for Immunotherapy to Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,423,194 | December 1, 2021 | February 28, 2026 | KIM, KEVIN KEEWOUN | reporter.nih.gov |
| BIOANALYTICAL SUPPORTS FOR A GLP TOX/BIODISTRIBUTION STUDY IN MINI-PIGS | NIH | National Institute on Drug Abuse | 2023 to 2024 | $2,412,735 | June 17, 2022 | December 31, 2024 | ROBERTSON, MIKE | reporter.nih.gov |
| LTBR CARs as next-generation therapies for R/R lymphoma | NIH | National Cancer Institute | 2023 to 2025 | $2,404,689 | April 10, 2023 | March 31, 2028 | SANJANA, NEVILLE | reporter.nih.gov |
| Targeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | NIH | National Cancer Institute | 2021 to 2025 | $2,401,768 | July 9, 2021 | June 30, 2026 | CALIGIURI, MICHAEL A | reporter.nih.gov |
| Deconstructing aging with senolytic CAR T cells | NIH | Office of the Director, National Institutes of Health | 2022 to 2025 | $2,400,000 | September 15, 2022 | August 31, 2027 | AMOR VEGAS, CORINA | reporter.nih.gov |
| Poly(amine-co-ester)s for Targeted Delivery In Vivo of Gene Editing Agents to Bone Marrow and Lung | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $2,399,844 | September 7, 2018 | August 31, 2024 | SALTZMAN, W. MARK | reporter.nih.gov |
| The IL-18-IFNγ axis predicts response to immunotherapy | NIH | National Cancer Institute | 2023 to 2025 | $2,399,099 | February 1, 2023 | January 31, 2028 | GUSTAFSON, HEATHER LEIGH HERD | reporter.nih.gov |
| Optimizing Surgical Transplant of CFTR Gene-Corrected Human Basal Stem Cells to the Upper Airway | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,392,495 | March 1, 2021 | January 31, 2027 | NAYAK, JAYAKAR V | reporter.nih.gov |
| HIV Reservoir and Gene Modified Cell Dynamics Following Autologous Stem Cell Transplantation | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,390,244 | January 13, 2023 | December 31, 2026 | HENRICH, TIMOTHY JENSEN | reporter.nih.gov |
| Escape from CAR T surveillance through lineage plasticity | NIH | National Cancer Institute | 2022 to 2025 | $2,388,454 | April 1, 2022 | March 31, 2027 | ERNST, PATRICIA | reporter.nih.gov |
| Oscillated Insertion Tool for Minimally Invasive, Low-Damage, Accurate Placement of Delivery Cannula to Improve Efficacy for DREADDS Therapy in Alcohol Addiction Treatment | NIH | National Institute on Alcohol Abuse and Alcoholism | 2024 to 2025 | $2,381,321 | September 1, 2022 | May 31, 2027 | BAGWELL, ROGER BROOKS | reporter.nih.gov |
| Functional Characterization and Development of Therapeutic Paradigms for DNA Damage Repair (DDR)-deficient Lethal Prostate Cancer | NIH | National Cancer Institute | 2023 to 2025 | $2,380,224 | April 1, 2023 | March 31, 2028 | CHAKRABORTY, GOUTAM | reporter.nih.gov |
| Novel strategy to block Nabs for AAV gene delivery | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,377,489 | March 1, 2022 | February 28, 2027 | LI, CHENGWEN | reporter.nih.gov |
| CRISPR/Cas9-based gene editing approaches for the treatment of USH2A-associated diseases | NIH | National Eye Institute | 2022 to 2025 | $2,373,472 | June 1, 2022 | May 31, 2027 | LIU, QIN | reporter.nih.gov |
| T cell migration and cardiovascular toxicity in immunotherapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,371,088 | July 22, 2019 | January 31, 2030 | KIM, MINSOO | reporter.nih.gov |
| Functional Genetics of the Neuronal Sodium Channel Gene SCN8A | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,368,240 | May 1, 1996 | January 31, 2027 | MEISLER, MIRIAM H | reporter.nih.gov |
| Directed Evolution of Novel AAVs and Regulatory Elements for Selective Microglial Gene Expression | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $2,362,638 | March 15, 2023 | February 29, 2028 | SCHAFFER, DAVID V | reporter.nih.gov |
| Genome Editing the Blood-Brain Barrier with Sonoselective Focused Ultrasound | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2024 | $2,361,933 | May 15, 2021 | July 31, 2025 | PRICE, RICHARD J. | reporter.nih.gov |
| Recognizing the tumor ecosystem: Integrating stromal and cancer antigen signals to achieve precision recognition of solid tumors by CAR T cells | NIH | National Cancer Institute | 2021 to 2025 | $2,360,524 | December 1, 2020 | November 30, 2026 | LIM, WENDELL A | reporter.nih.gov |
| Control of Breathing and Pompe Disease | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $2,360,520 | February 15, 2007 | April 30, 2026 | BYRNE, BARRY J | reporter.nih.gov |
| CGT and ACD Inhibitors for SRT Treatment of Krabbe Disease | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,357,715 | September 22, 2022 | August 31, 2027 | BONGARZONE, ERNESTO ROQUE | reporter.nih.gov |
| Translating Autoantibodies Into Chimeric Antigen Receptor-T cell Therapy for Small Cell Lung Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,357,606 | September 1, 2022 | August 31, 2027 | LASTWIKA, KRISTIN J | reporter.nih.gov |
| The Landscape of Tumor intrinsic Genetic Resistance to T cell Therapy | NIH | National Cancer Institute | 2023 to 2025 | $2,350,290 | May 1, 2023 | April 30, 2027 | HINRICHS, CHRISTIAN | reporter.nih.gov |
| Developing a platform for human somatic cell rejuvenation, expansion and genetic engineering using synthetic RNA molecules | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $2,346,523 | May 1, 2021 | April 30, 2027 | KOGUT, IGOR | reporter.nih.gov |
| Circuit-Specific Delivery of Large Cargo Across the Nervous Systems of Adult Mammals and Embryos via Novel Engineered Systemic Vectors | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $2,345,000 | September 30, 2018 | August 31, 2024 | GRADINARU, VIVIANA | reporter.nih.gov |
| The Jackson Laboratory Gene Editing Testing Center (JAX-GETC) | NIH | Office of the Director, National Institutes of Health | 2021 to 2022 | $2,344,241 | September 18, 2018 | July 31, 2024 | MURRAY, STEPHEN A | reporter.nih.gov |
| Nonhuman Primate Model of Inherited Photoreceptor Degeneration | NIH | National Eye Institute | 2023 to 2025 | $2,341,778 | September 30, 2023 | March 31, 2027 | MCGILL, TREVOR JACKSON | reporter.nih.gov |
| Developing three-dimensional antisense oligonucleotide drugs against COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,341,581 | July 19, 2021 | June 30, 2026 | GUO, FENG | reporter.nih.gov |
| A novel CAR-T cell therapy for the one-time treatment of chronic HIV infection in patients who are not ART suppressed | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,334,499 | February 13, 2024 | January 31, 2026 | ATHANASIOU, MARIA CONSTANCE | reporter.nih.gov |
| Chemotherapy-free cure of hemoglobin disorders through base editing | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,334,252 | September 1, 2023 | May 31, 2027 | BAUER, DANIEL EVAN | reporter.nih.gov |
| Ultrasound-mediated gene delivery to achieve therapeutic correction of hemophilia A | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,322,835 | April 1, 2020 | March 31, 2026 | MIAO, CAROL H | reporter.nih.gov |
| Immunotherapeutic targeting of gangliosides in Ewing Sarcoma | NIH | National Cancer Institute | 2023 to 2025 | $2,317,710 | September 19, 2023 | August 31, 2028 | MAJZNER, ROBBIE G. | reporter.nih.gov |
| Systemic delivery of siRNA by Nanosac for checkpoint blockade immunotherapy of head and neck squamous cell cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,315,370 | February 1, 2021 | January 31, 2026 | YEO, YOON | reporter.nih.gov |
| Directed evolution of a sequence-specific targeting technology for therapeutic gene delivery to the human genome. | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2024 | $2,313,515 | May 1, 2021 | January 31, 2026 | OWENS, JESSE BRUCE | reporter.nih.gov |
| Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS) | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $2,309,830 | September 19, 2023 | August 31, 2026 | MURAD, JOANA M | reporter.nih.gov |
| A cross-species preclinical platform to enhance the translation of new medicines | NIH | National Center for Advancing Translational Sciences | 2023 to 2025 | $2,306,784 | December 1, 2023 | November 30, 2026 | GEISSE, NICHOLAS ANDREW | reporter.nih.gov |
| AnteroTag, a Novel Method for Trans-Synaptic Delivery of Active Agents to Map and Modify Anterograde Populations | NIH | National Institute of Mental Health | 2021 | $2,304,752 | September 13, 2021 | September 12, 2025 | WILLIAMS, MICHAEL ROLAND | reporter.nih.gov |
| Training In Cell and Gene Therapy | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,300,213 | July 1, 2003 | July 31, 2028 | HESLOP, HELEN E | reporter.nih.gov |
| Toward GMP production of antigen specific regulatory T cells | NIH | National Cancer Institute | 2021 to 2023 | $2,300,003 | September 3, 2021 | October 31, 2024 | SHI, GUIXIN | reporter.nih.gov |
| Mechanism of immune response to muscle-directed AAV gene transfer | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,292,756 | May 19, 2023 | April 30, 2028 | HERZOG, ROLAND W. | reporter.nih.gov |
| Novel CAR T cell engineering strategies for effective eradication of solid and liquid tumors | NIH | National Cancer Institute | 2021 to 2025 | $2,291,623 | September 20, 2019 | May 31, 2030 | MAUS, MARCELA VALDERRAMA | reporter.nih.gov |
| Life-long phenotypic correction of CF airways | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,290,437 | August 1, 2017 | February 28, 2027 | SINN, PATRICK L | reporter.nih.gov |
| Full human gene-replacement mouse models of ADRDs | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $2,280,898 | September 18, 2019 | August 31, 2025 | KOOB, MICHAEL D | reporter.nih.gov |
| Protein depleting pre-existing antibodies for viral gene therapy | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,276,317 | August 1, 2023 | July 31, 2026 | MCCARTY, DOUGLAS M | reporter.nih.gov |
| HORMAD-specific TGF-beta resistant memory T cells for treatment of patients with Gastro-esophageal Cancer | NIH | National Cancer Institute | 2025 | $2,270,520 | September 19, 2023 | August 31, 2028 | YEE, CASSIAN | reporter.nih.gov |
| Combine mitochondrial gene therapy and synthetic lethal chemotherapy to treat triple-negative breast cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,266,573 | June 10, 2022 | May 31, 2027 | LIU, XIAOGUANG MARGARET | reporter.nih.gov |
| T cell-targeted lentiviral vectors with Cas9/RNP for the in vivo gene therapy of HIV-AIDS | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,261,355 | January 23, 2019 | December 31, 2025 | KUMAR, PRITI | reporter.nih.gov |
| Synthetic metabolism to armor and enhance a new class of cell therapies | NIH | National Cancer Institute | 2022 to 2025 | $2,260,963 | September 8, 2022 | August 31, 2027 | BLAZECK, JOHN JAMES | reporter.nih.gov |
| Spherical Nucleic Acid nano-architectures as first-in-class cGAS agonists for the immunotherapeutic treatment of Glioblastoma. | NIH | National Cancer Institute | 2022 to 2025 | $2,256,713 | September 23, 2022 | August 31, 2027 | STEGH, ALEXANDER H. | reporter.nih.gov |
| Unraveling the pathogenesis of familial dilated cardiomyopathy towards precision medicine | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,249,910 | July 1, 2018 | January 31, 2027 | KARAKIKES, IOANNIS | reporter.nih.gov |
| Engineering Tregs for autoimmune diabetes therapy | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $2,249,376 | September 5, 2025 | August 31, 2028 | FIFE, BRIAN T | reporter.nih.gov |
| Engineering In Vivo Chimeric Antigen Receptor Macrophages (CARMs) using mRNA-exosomes for Cancer Immunotherapy | NIH | National Cancer Institute | 2023 to 2025 | $2,242,875 | August 1, 2023 | July 31, 2027 | JIANG, WEN | reporter.nih.gov |
| Next generation T cell therapies for mutant KRAS solid tumors | NIH | National Cancer Institute | 2025 | $2,238,704 | September 1, 2025 | August 31, 2028 | CARRENO, BEATRIZ M. | reporter.nih.gov |
| Decoding and reprogramming T cells through synthetic biology for cancer immunotherapy | NIH | National Cancer Institute | 2023 to 2025 | $2,232,473 | January 1, 2023 | December 31, 2027 | MARSON, ALEXANDER | reporter.nih.gov |
| Targeting Effector Immune cells to Cancer with Chemically Self-Assembled Nanorings (CSANs) | NIH | National Cancer Institute | 2021 to 2024 | $2,229,339 | March 1, 2020 | June 30, 2025 | WAGNER, CARSTON R. | reporter.nih.gov |
| Novel Nanomedicine-Based Therapeutic Approach For Treatment of Cancer Cachexia | NIH | National Cancer Institute | 2021 to 2025 | $2,226,892 | May 1, 2024 | April 30, 2027 | TARATULA, OLEH | reporter.nih.gov |
| Targeting virus-specific CAR T cells to lymphoid follicles to achieve durable HIV suppression | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,223,444 | November 13, 2018 | October 31, 2024 | SKINNER, PAMELA J | reporter.nih.gov |
| A Platform Technology to Genetically Reprogram Cancer Cells for Enhanced Immunotherapy | NIH | National Cancer Institute | 2021 to 2025 | $2,221,249 | July 1, 2025 | June 30, 2027 | TZENG, STEPHANY YI | reporter.nih.gov |
| Enhancer AAV-based genetic access and manipulation of specific brain cell types implicated in aging and Alzheimer's Disease | NIH | National Institute on Aging | 2025 | $2,220,145 | September 1, 2025 | August 31, 2027 | XU, XIANGMIN | reporter.nih.gov |
| Rational in situ programming of cancer vaccine-responding T-cell clones | NIH | National Cancer Institute | 2021 to 2025 | $2,219,015 | July 1, 2021 | June 30, 2026 | STEPHAN, MATTHIAS | reporter.nih.gov |
| Multiplex base/prime editors for in vivo selection of modified HSPCs in hemoglobinopathy | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $2,218,334 | January 17, 2017 | December 31, 2025 | KIEM, HANS-PETER | reporter.nih.gov |
| The circadian rhythm as a lentiviral vector restriction factor | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,217,413 | September 1, 2020 | August 31, 2026 | KAFRI, TAL | reporter.nih.gov |
| Resubmission - Development and scale-up of Continuous Countercurrent Tangential Chromatography (CCTC) for next generation AAV vector manufacturing (Direct to Phase II) | NIH | National Institute of General Medical Sciences | 2024 to 2025 | $2,214,324 | May 15, 2024 | February 28, 2026 | SHINKAZH, OLEG | reporter.nih.gov |
| Improving genetically engineered T cells for medulloblastomas | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,210,532 | April 15, 2021 | April 30, 2026 | KRENCIUTE, GIEDRE | reporter.nih.gov |
| Development and validation of AAV vectors to manipulate specific neuronal subtypes and circuits involved in epilepsy and psychiatric disorders across mammalian species. | NIH | National Institute of Mental Health | 2021 | $2,208,603 | August 22, 2019 | November 30, 2022 | FISHELL, GORDON J | reporter.nih.gov |
| Conditional control of universal antigen receptor signaling | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,206,336 | September 15, 2021 | August 31, 2026 | LOHMUELLER, JASON JAKOB | reporter.nih.gov |
| Harnessing the thymus for long-term tumor control with hematopoietic stem cell-derived naive CAR T cells | NIH | National Cancer Institute | 2022 to 2025 | $2,202,507 | March 1, 2022 | January 31, 2027 | ZAKRZEWSKI, JOHANNES | reporter.nih.gov |
| Implications of Genetic Diversity in Muscular Dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2024 | $2,200,578 | September 1, 2021 | August 31, 2026 | KEMALADEWI, DWI UTAMI | reporter.nih.gov |
| Role of disrupted ASL pH regulation in small airways in CF lung disease pathogenesis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,193,211 | August 15, 2021 | July 31, 2025 | LI, XIAOPENG | reporter.nih.gov |
| Understanding and Controlling the Contribution of Fibrinolysis to Bleeding Using a Long-Acting Antifibrinolytic RNA Therapy | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,182,730 | August 15, 2023 | July 31, 2027 | KASTRUP, CHRISTIAN | reporter.nih.gov |
| Genetic Approach to Therapy for DFNA9 | NIH | National Institute on Deafness and Other Communication Disorders | 2023 to 2025 | $2,180,163 | April 20, 2023 | March 31, 2028 | MORTON, CYNTHIA CASSON | reporter.nih.gov |
| Platelet-derived FVIII Gene Therapy of Hemophilia A | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,174,848 | July 1, 2010 | June 30, 2028 | SHI, QIZHEN | reporter.nih.gov |
| Exploring the potential of TET inhibition in cancer immunotherapy | NIH | National Cancer Institute | 2021 to 2024 | $2,169,214 | July 1, 2020 | June 30, 2025 | RAO, ANJANA | reporter.nih.gov |
| Gene Therapy Delivery for Age-related Neurodegenerative Diseases | NIH | National Institute on Aging | 2023 to 2025 | $2,166,681 | June 1, 2023 | February 29, 2028 | BAILEY, RACHEL M | reporter.nih.gov |
| Expression of recombinant Fc receptors by engineered NK cells to enhance cancer cell killing | NIH | National Cancer Institute | 2021 to 2025 | $2,162,801 | January 1, 2016 | March 31, 2027 | WALCHECK, BRUCE K | reporter.nih.gov |
| RNAi Therapy for Spinocerebellar Ataxia Type 1 | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $2,161,314 | January 1, 2016 | August 31, 2025 | DAVIDSON, BEVERLY L. | reporter.nih.gov |
| Gene therapy targeting striatal dysfunction for Parkinson’s disease | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,153,443 | February 1, 2022 | January 31, 2027 | PAPA, STELLA M | reporter.nih.gov |
| IND-enabling studies for Aspartylglucosaminuria (AGU) to support the initiation of an AAV9/AGA gene transfer clinical trial | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $2,149,389 | September 1, 2023 | August 31, 2027 | GRAY, STEVEN J | reporter.nih.gov |
| Interrogating the in vivo pharmacokinetics of armored CARs with radiohapten capture | NIH | National Cancer Institute | 2021 to 2024 | $2,149,252 | July 7, 2021 | January 1, 2025 | KREBS, SIMONE | reporter.nih.gov |
| Development of a treatment for the durable remission of HIV using autologous human CAR T cells that target B cell follicles | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,147,058 | June 18, 2020 | July 31, 2024 | ATHANASIOU, MARIA CONSTANCE | reporter.nih.gov |
| Development of Technologies for Efficient In Vivo Prime Editing | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $2,144,906 | April 1, 2021 | February 28, 2026 | PEREZ-PINERA, PABLO | reporter.nih.gov |
| Vascular Regeneration with Direct Reprogramming and Engineering Strategies | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,143,183 | August 1, 2022 | July 31, 2026 | YOON, YOUNG-SUP | reporter.nih.gov |
| Systemic Delivery of Targeted Bi-Compartmental Nanoparticles for Glioblastoma Therapeutics | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,142,892 | March 15, 2022 | February 28, 2027 | LAHANN, JOERG | reporter.nih.gov |
| Tissue Adhesive RNA Interference Nanoparticles to Block Progression of Posttraumatic and Spontaneous Osteoarthritis. | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $2,136,077 | August 22, 2022 | July 31, 2027 | DUVALL, CRAIG LEWIS | reporter.nih.gov |
| Toward development of senolytic CAR T cells | NIH | National Institute on Aging | 2021 to 2024 | $2,133,137 | May 15, 2020 | February 28, 2025 | LOWE, SCOTT W. | reporter.nih.gov |
| Unraveling the Pathophysiology of Neurotoxicity Induced by CAR T-cells | NIH | National Cancer Institute | 2022 to 2025 | $2,131,216 | August 8, 2022 | July 31, 2027 | PENNELL, CHRISTOPHER A | reporter.nih.gov |
| AAV-mediated Interrogation of the Brain FSH Receptor | NIH | National Institute on Aging | 2025 | $2,129,396 | August 1, 2025 | July 31, 2027 | YUEN, TONY | reporter.nih.gov |
| Harnessing Supercoiling to Regulate DNA Activity | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,128,539 | September 15, 2021 | July 31, 2027 | ZECHIEDRICH, LYNN | reporter.nih.gov |
| A Xenopus Laevis Research Resource for Immunobiology | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,125,313 | June 1, 2004 | July 31, 2028 | ROBERT, JACQUES | reporter.nih.gov |
| Targeting HIV-specific CAR T cells to the gut for the durable remission of HIV | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,120,489 | April 1, 2023 | March 31, 2028 | SKINNER, PAMELA J | reporter.nih.gov |
| Towards rational design of combination therapeutic targets | NIH | National Cancer Institute | 2021 to 2024 | $2,120,092 | June 1, 2020 | May 31, 2025 | TAN, KAI | reporter.nih.gov |
| Macrophage-targeting Nanoplatforms as Immunotherapy against Pulmonary Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,117,352 | July 1, 2017 | November 30, 2028 | SAILOR, MICHAEL J | reporter.nih.gov |
| A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesothelioma | NIH | National Cancer Institute | 2021 to 2024 | $2,116,571 | June 1, 2019 | May 31, 2025 | ADUSUMILLI, PRASAD S. | reporter.nih.gov |
| Ligand-Directed KRAS G12V Mutant-Specific Therapeutics | NIH | National Cancer Institute | 2023 to 2025 | $2,113,685 | July 5, 2023 | June 30, 2026 | STANLAND, LYLA | reporter.nih.gov |
| Development of CRISPR/Cas9-based exon-skipping strategies for the treatment of USH-associated deafness | NIH | National Institute on Deafness and Other Communication Disorders | 2022 to 2024 | $2,113,099 | August 22, 2022 | June 30, 2027 | LIU, XUE Z | reporter.nih.gov |
| Advancing CAR T cell therapy for solid tumors | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $2,112,916 | September 14, 2021 | August 31, 2026 | AHMED, JALAL | reporter.nih.gov |
| Testing Optimal Gene Editor for an Alzheimer's CRISPR therapeutic. | NIH | National Institute of Neurological Disorders and Stroke | 2023 | $2,112,826 | September 1, 2023 | August 31, 2026 | ROY, SUBHOJIT | reporter.nih.gov |
| Oncolytic Virus Therapeutic Responses Occur from Changes in the Glioblastoma Immune Microenvironment | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,109,872 | September 15, 2019 | February 28, 2029 | CHIOCCA, E. ANTONIO | reporter.nih.gov |
| Engineering synthetic cellular crosstalk for transplantation tolerance | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,109,666 | February 1, 2022 | January 31, 2027 | MA, LEYUAN | reporter.nih.gov |
| Novel methods to improve nuclease mediated homologous recombination | NIH | National Institute of General Medical Sciences | 2022 to 2023 | $2,108,514 | August 1, 2017 | March 31, 2025 | ZHANG, JIFENG | reporter.nih.gov |
| Brain-Imaging Markers of Neurotoxicity and Long-Term Outcomes after CAR-T Cell Therapy | NIH | National Cancer Institute | 2023 to 2025 | $2,106,587 | April 1, 2023 | March 31, 2028 | BANSAL, RAVI | reporter.nih.gov |
| Missense Variants in Myosin Binding Protein C that Cause Hypertrophic Cardiomyopathy | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,100,429 | September 1, 2023 | August 31, 2027 | DAY, SHARLENE M | reporter.nih.gov |
| Thyroid Physiology Studies of Inherited Disorders | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,100,251 | July 15, 1979 | December 31, 2027 | REFETOFF, SAMUEL | reporter.nih.gov |
| Structural basis of BBSome-mediated ciliary exit | NIH | National Eye Institute | 2021 to 2023 | $2,085,339 | June 1, 2020 | May 31, 2024 | NACHURY, MAXENCE V | reporter.nih.gov |
| Advancing allogeneic CAR-iNKT for the treatment of solid tumors through comparative oncology | NIH | National Cancer Institute | 2022 to 2025 | $2,083,891 | September 1, 2022 | August 31, 2027 | MASON, NICOLA J | reporter.nih.gov |
| Engineering CAR-B cells for an HIV-1 functional cure | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,079,056 | August 1, 2022 | May 31, 2027 | FARZAN, MICHAEL R. | reporter.nih.gov |
| Assembly of Novel Gene Editing Particles to Understand Genome Surgery in Patient-Derived Cells | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,078,314 | August 19, 2016 | May 31, 2026 | SAHA, KRISHANU | reporter.nih.gov |
| New Materials to Deliver mRNA: Applications in Cancer Immunotherapy | NIH | National Cancer Institute | 2021 to 2024 | $2,075,015 | August 13, 2020 | April 30, 2025 | WAYMOUTH, ROBERT M. | reporter.nih.gov |
| MODULATION OF CD5 SIGNALING TO ENHANCE ADOPTIVE T-CELL THERAPIES FOR CANCER | NIH | National Cancer Institute | 2022 to 2025 | $2,073,174 | April 12, 2022 | March 31, 2027 | RUELLA, MARCO | reporter.nih.gov |
| EPIGENETIC REPROGRAMMING OF T CELL EXHAUSTION TO ENHANCE TUMOR IMMUNOTHERAPY | NIH | National Cancer Institute | 2021 to 2025 | $2,070,977 | March 1, 2020 | March 31, 2030 | YOUNGBLOOD, BENJAMIN ALAN | reporter.nih.gov |
| Determinants of AAV Tropism | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,067,025 | December 12, 2008 | April 30, 2028 | ASOKAN, ARAVIND | reporter.nih.gov |
| Ten-Fold Resolution Boost for Magnetic Particle Imaging with Applications to Rapid, Non-Invasive Imaging of CAR-T Cell Therapies, Stroke, GI Bleeds and Pulmonary Embolisms | NIH | National Institute of Biomedical Imaging and Bioengineering | 2023 to 2025 | $2,065,916 | September 15, 2023 | August 31, 2028 | CONOLLY, STEVEN M | reporter.nih.gov |
| AAV capsids and their cellular interactions | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,064,315 | September 17, 2007 | January 31, 2028 | MCKENNA, ROBERT | reporter.nih.gov |
| Deciphering unintended large gene modifications in gene editing for sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,057,558 | July 1, 2023 | June 30, 2027 | BAO, GANG | reporter.nih.gov |
| Engineering AAV capsids for enhanced transduction of skeletal muscle | NIH | National Center for Advancing Translational Sciences | 2021 to 2023 | $2,056,445 | September 1, 2020 | February 29, 2024 | ALPERT, MICHAEL DAVID | reporter.nih.gov |
| Enhancing cone survival in retinitis pigmentosa through cell-specific therapeutic CRISPR editing of a roxadustat target | NIH | National Eye Institute | 2022 to 2025 | $2,055,441 | June 1, 2022 | May 31, 2027 | TSANG, STEPHEN H | reporter.nih.gov |
| CAR T cells targeting mesothelin and secreting bispecific antibodies targeting fibroblasts in pancreatic cancer | NIH | National Cancer Institute | 2025 | $2,054,733 | September 1, 2025 | August 31, 2028 | MAUS, MARCELA VALDERRAMA | reporter.nih.gov |
| Regulation of Zbtb44-Eomes complex in CD8+T cells and anti-tumor immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,053,464 | March 24, 2021 | February 28, 2027 | POOJARY, VENUPRASAD K | reporter.nih.gov |
| Targeting tumor and T cell DNA methylomes to improve CAR T cell therapies for diffuse midline glioma | NIH | National Cancer Institute | 2023 to 2025 | $2,052,826 | September 7, 2023 | August 31, 2028 | MACK, STEPHEN C | reporter.nih.gov |
| Bone marrow-targeted extracellular vesicles as a novel non-viral gene editor delivery platform | NIH | National Center for Advancing Translational Sciences | 2022 to 2023 | $2,051,588 | July 1, 2022 | May 31, 2025 | THON, JONATHAN N | reporter.nih.gov |
| Novel CART Cells for Treating AML | NIH | National Cancer Institute | 2022 to 2025 | $2,049,319 | June 1, 2022 | May 31, 2027 | HUA, XIANXIN | reporter.nih.gov |
| Smart nanoparticles regulating oncogenic IncRNA for breast cancer therapy | NIH | National Cancer Institute | 2021 to 2025 | $2,041,762 | December 12, 2018 | November 30, 2028 | LU, ZHENG-RONG | reporter.nih.gov |
| Map Leukemia-immune Cell Talks with Nanoplasmon Ruler in CAR T-Cell Immunotherapy | NIH | National Cancer Institute | 2021 to 2024 | $2,039,396 | July 1, 2020 | June 30, 2025 | CHEN, WEIQIANG | reporter.nih.gov |
| Transcriptional Control of T Cell Function | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,037,700 | March 22, 2021 | February 28, 2027 | SCOTT-BROWNE, JAMES | reporter.nih.gov |
| Innovative Research for Cancer Nanotechnology (IRCN) for Enhancing Melanoma-specific Immune Responses by the Rational Design of Spherical Nucleic Acids | NIH | National Cancer Institute | 2022 to 2025 | $2,035,485 | March 14, 2022 | February 28, 2027 | MIRKIN, CHAD A. | reporter.nih.gov |
| In Vivo Gene Editing for HIV-1 Cure | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,034,027 | February 11, 2019 | January 31, 2025 | CHEN, IRVIN S.Y. | reporter.nih.gov |
| Optimizing and validation of gene therapy vectors to treat limb girdle muscular dystophy | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,025,915 | August 1, 2020 | April 30, 2026 | SPENCER, MELISSA JAN | reporter.nih.gov |
| NON-CLINICAL SAFETY ASSESSMENT OF GENE THERAPY (PCCA, MMAB, DOK7 AND COLQ) TO SUPPORT PLATFORM GENE THERAPY FOR CONGENITAL MYASTHENIC DISEASES (DOK7, COLQ) AND ACIDEMIA (PCCA, MMAB) | NIH | Office of the Director, National Institutes of Health | 2025 | $2,024,745 | September 25, 2020 | May 24, 2026 | reporter.nih.gov | |
| Multimodal AI modeling of T cell therapies to predict patient response and nominate advanced cell design strategies | NIH | Office of the Director, National Institutes of Health | 2025 | $2,019,991 | January 23, 2025 | January 22, 2026 | MACKALL, CRYSTAL | reporter.nih.gov |
| CAR T Cells for Advanced Thyroid Cancer | NIH | National Cancer Institute | 2021 to 2023 | $2,016,676 | April 23, 2021 | June 30, 2023 | JIN, MOONSOO M. | reporter.nih.gov |
| Probiotic guided CAR-T therapy (ProCARs) for breast cancer | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2023 | $2,016,458 | September 15, 2020 | May 31, 2024 | DANINO, TAL | reporter.nih.gov |
| Molecular determinants of cellular heterogeneity and therapeutic resistance in GBM. | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,014,849 | April 15, 2021 | January 31, 2026 | LOPEZ-BERTONI, HERNANDO MARTIN | reporter.nih.gov |
| Defining the molecular interactions within nanoparticles that enable delivery of long nucleic acids | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2025 | $2,012,253 | August 1, 2018 | October 31, 2026 | SIEGWART, DANIEL JOHN | reporter.nih.gov |
| Harnessing the power of exosomes for non-coding RNA delivery | NIH | National Cancer Institute | 2021 to 2023 | $2,011,604 | August 2, 2017 | July 31, 2025 | SOOD, ANIL K | reporter.nih.gov |
| Enhancing engineered T cell therapeutic efficacy for the treatment of pancreatic ductal adenocarcinoma | NIH | National Cancer Institute | 2021 to 2025 | $2,010,185 | September 16, 2021 | July 31, 2027 | STROMNES, INGUNN MARGARETE | reporter.nih.gov |
| Setting the Stage for Replacement of Mitochondrial Genes | NIH | National Eye Institute | 2021 to 2025 | $2,004,064 | December 1, 1994 | August 31, 2027 | MORAES, CARLOS TORRES | reporter.nih.gov |
| Mechanism and function of small RNAs in development and gene silencing in the germline | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,001,454 | August 11, 2016 | May 31, 2027 | MONTGOMERY, TAIOWA AKONI | reporter.nih.gov |
| Multiscale considerations for immune engineering at mucosal interfaces | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,000,000 | July 2, 2021 | May 31, 2026 | FROMEN, CATHERINE A | reporter.nih.gov |
| In Situ Tumor Vaccination with a Nano-oligo Therapeutic to Induce Whole-body Antitumor Immune Response | NIH | National Cancer Institute | 2021 to 2022 | $2,000,000 | September 1, 2021 | February 29, 2024 | NGAMCHERDTRAKUL, WORAPOL | reporter.nih.gov |
| Next Generation Autologous TIL Cancer Therapy: Development of GMP manufacturing process | NIH | National Cancer Institute | 2022 to 2023 | $2,000,000 | September 1, 2022 | August 31, 2025 | DUKE, RICHARD C | reporter.nih.gov |
| Development of CD4 TCR-engineered T cell immunotherapy in triple-negative breast cancer | NIH | National Cancer Institute | 2024 to 2025 | $2,000,000 | September 20, 2024 | August 31, 2027 | WANG, YICHENG | reporter.nih.gov |
| TOPIC 414 : SYNTHETIC BIOLOGY GENE CIRCUITS FOR CANCER THERAPY | NIH | National Cancer Institute | 2021 | $1,999,993 | August 1, 2021 | July 31, 2023 | LEE, GARY | reporter.nih.gov |
| CTO1681 to prevent and mitigate cytokine release syndrome in CAR T-cell recipients | NIH | National Cancer Institute | 2024 to 2025 | $1,999,990 | September 20, 2024 | August 31, 2026 | BERTOLINO, ARTHUR P | reporter.nih.gov |
| Dual-targeting allogeneic CAR T-cells for universal therapy of T-cell malignancies | NIH | National Cancer Institute | 2024 to 2025 | $1,999,703 | September 1, 2024 | August 31, 2027 | HEIN, SARAH MARIE | reporter.nih.gov |
| TOPIC 397 - MICROFLUIDIC VORTEX SHEDDING: A LOW-COST, HIGH EFFICIENCY METHOD FOR GENETIC MODIFICATION TO SUPPORT CELL ENGINEERING FOR CELL-BASED IMMUNOTHERAPIES | NIH | National Cancer Institute | 2022 | $1,999,646 | September 19, 2022 | September 18, 2024 | PAWELL, RYAN | reporter.nih.gov |
| GENETICALLY ENGINEERED T CELLS FOR DIPG | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,999,395 | August 1, 2022 | July 31, 2027 | KRENCIUTE, GIEDRE | reporter.nih.gov |
| A Phase 1, Open Label, Multicenter Trial to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory CD20+ B-Cell NHL or CLL | NIH | National Cancer Institute | 2021 to 2022 | $1,998,672 | September 16, 2021 | August 31, 2023 | LITCHMAN, MANUEL | reporter.nih.gov |
| Gene Editing and Silencing in Phototransduction | NIH | National Eye Institute | 2021 to 2025 | $1,998,605 | September 1, 2015 | June 30, 2027 | TSANG, STEPHEN H | reporter.nih.gov |
| Intravitreal gene therapy for inherited retinal disease | NIH | National Eye Institute | 2023 to 2025 | $1,994,753 | July 1, 2023 | May 31, 2028 | MOSHIRI, ALA | reporter.nih.gov |
| Immunoengineering Next-Generation Cancer Therapies with Focused Ultrasound | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $1,994,626 | September 14, 2021 | February 28, 2027 | SHEYBANI, NATASHA DIBA | reporter.nih.gov |
| Evolving High Potency AAV Vectors for Neuromuscular Genome Editing | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2022 | $1,992,277 | September 10, 2018 | July 31, 2024 | ASOKAN, ARAVIND | reporter.nih.gov |
| Next generation transposon vectors for genome engineering | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $1,990,139 | September 1, 2022 | May 31, 2027 | WILSON, MATTHEW H | reporter.nih.gov |
| MicroRNA Therapeutics for Traumatic Brain Injury | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,987,816 | February 15, 2020 | January 31, 2026 | LIU, DAZHI JEFF | reporter.nih.gov |
| Development of Genome Editing as Treatment for Genetic Hearing Loss | NIH | National Institute on Deafness and Other Communication Disorders | 2021 to 2023 | $1,986,713 | January 1, 2019 | December 31, 2024 | CHEN, ZHENG-YI | reporter.nih.gov |
| Adaptable and scalable electroporation for cellular therapy | NIH | National Institute of General Medical Sciences | 2024 to 2025 | $1,986,049 | July 1, 2022 | July 31, 2027 | CRAIGHEAD, HAROLD G | reporter.nih.gov |
| Transcriptional Regulation of Endothelial Cells after Neonatal Lung Injury | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,984,340 | April 1, 2018 | June 30, 2027 | KALINICHENKO, VLADIMIR | reporter.nih.gov |
| Developing Long Noncoding RNA Therapy for Precision Cardiac Repair | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,982,431 | April 1, 2019 | August 31, 2027 | CHENG, KE | reporter.nih.gov |
| Breast Cancer Brain Metastasis Therapy by Focused Ultrasound-Guided Control of HER2 CAR T cells | NIH | National Cancer Institute | 2023 to 2025 | $1,982,412 | June 8, 2023 | May 31, 2028 | ARVANITIS, KONSTANTINOS-COSTAS | reporter.nih.gov |
| Efficacy and safety of nanoparticle mediated placental gene therapy in nonhuman primates | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 to 2025 | $1,980,428 | August 7, 2023 | April 30, 2028 | JONES, HELEN N | reporter.nih.gov |
| DNA-gated cytometry for multiplexed sorting of antigen-specific CD8 T cells | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,977,500 | June 20, 2022 | May 31, 2027 | KWONG, GABRIEL A | reporter.nih.gov |
| MicroRNA lipid-nanoparticle based therapy targets neuroinflammation and ApoE dysregulation in Alzheimer’s disease | NIH | National Institute on Aging | 2023 to 2025 | $1,975,255 | April 15, 2023 | December 31, 2027 | WANG, WANG-XIA | reporter.nih.gov |
| Autophagon: an Autophagy-Functionalizing Gene Therapy Tool for Neurodegenerative Diseases | NIH | National Institute on Aging | 2023 to 2025 | $1,972,119 | March 15, 2022 | December 31, 2026 | YAKOUB, ABRAAM M. | reporter.nih.gov |
| Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants | NIH | National Cancer Institute | 2021 to 2025 | $1,970,730 | February 1, 2021 | January 31, 2027 | FUEYO, JUAN | reporter.nih.gov |
| Acoustothermogenetics for Cell Engineering | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $1,969,916 | June 1, 2021 | May 31, 2027 | WANG, YINGXIAO | reporter.nih.gov |
| Nanoparticle delivery of miRNA-based therapeutics to overcome clinical challenges in triple negative breast cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,969,673 | March 4, 2021 | February 28, 2027 | WANG, ZHIHUI | reporter.nih.gov |
| Therapeutic use of an enhanced form of CD4-Ig | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,968,801 | December 4, 2020 | May 31, 2026 | FARZAN, MICHAEL R. | reporter.nih.gov |
| Combination antigen sensing engineered T cell for precise recognition and enhanced elimination of solid tumors | NIH | National Cancer Institute | 2023 to 2025 | $1,965,246 | April 4, 2023 | March 31, 2028 | ROYBAL, KOLE T | reporter.nih.gov |
| Studies in Poxvirus Host Range Genes and Tropism | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,962,500 | March 16, 2009 | May 31, 2027 | RAHMAN, MASMUDUR MOHAMMED | reporter.nih.gov |
| Systemic delivery of an oncolytic adenovirus targeting TGFβ to enhance anti-PD-1 and anti-CTLA-4 therapy for triple negative breast cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,961,125 | March 1, 2021 | February 28, 2027 | XU, WEIDONG | reporter.nih.gov |
| VEGF Gene Delivery In The Primate To Prevent Defective Spiral Artery Remodeling And Maternal Vascular Dysfunction | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $1,958,338 | September 8, 2017 | March 31, 2029 | ABERDEEN, GRAHAM W | reporter.nih.gov |
| Toward Translation of an Immunotherapeutic Nanomedicine for Neuroblastoma | NIH | National Cancer Institute | 2022 to 2025 | $1,952,176 | July 1, 2022 | June 30, 2027 | WILSON, JOHN TANNER | reporter.nih.gov |
| Pluripotent Stem Cell Derived 3D Retinas for Studies of Early Onset Retinal Degeneration | NIH | National Eye Institute | 2021 to 2024 | $1,950,685 | April 1, 2020 | March 31, 2026 | WAHLIN, KARL J | reporter.nih.gov |
| Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites) (U24 Clinical Trial Not Allowed) | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,950,438 | July 15, 2018 | June 30, 2028 | MARDER, KAREN S | reporter.nih.gov |
| Engineered T cell-based imaging for glioblastoma and CAR-T cell tracking | NIH | National Cancer Institute | 2023 to 2025 | $1,946,230 | September 21, 2023 | August 31, 2027 | ROYBAL, KOLE T | reporter.nih.gov |
| Clinical evaluation of IL13Ra2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant glioma | NIH | National Cancer Institute | 2021 to 2024 | $1,945,311 | January 1, 2019 | December 31, 2025 | BROWN, CHRISTINE | reporter.nih.gov |
| Energetic State and Metabolic Remodeling in Cardiac Hypertrophy and Failure | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,940,909 | September 14, 2022 | June 30, 2027 | YANG, QINGLIN | reporter.nih.gov |
| Modulating the PD-1/PD-L1 checkpoint to promote antitumor activity of HER2 CAR T cells in patients with sarcoma | NIH | National Cancer Institute | 2023 to 2025 | $1,938,900 | March 7, 2023 | February 29, 2028 | HEGDE, MEENAKSHI G | reporter.nih.gov |
| Vestibular dysfunction and the development of therapies for Usher syndrome | NIH | National Institute on Deafness and Other Communication Disorders | 2023 to 2025 | $1,938,657 | January 1, 2023 | December 31, 2027 | LENTZ, JENNIFER JEAN | reporter.nih.gov |
| Development of a DCLK1 siRNA Nanoparticle as Targeted Therapy to Treat Pancreatic Cancer | NIH | National Cancer Institute | 2021 to 2022 | $1,935,472 | August 22, 2018 | July 31, 2024 | DE OLIVEIRA, ELISEU O. | reporter.nih.gov |
| Defining Barriers to Gene Therapy | NIH | National Eye Institute | 2021 to 2025 | $1,933,185 | September 1, 2008 | May 31, 2027 | TSANG, STEPHEN H | reporter.nih.gov |
| AAV capsid-promoter interactions determines CNS cell selective gene expression in vivo | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,932,088 | December 15, 2020 | November 30, 2026 | MCCOWN, THOMAS J. | reporter.nih.gov |
| Quantitative protein network profiling to improve CAR design and efficacy | NIH | National Cancer Institute | 2021 to 2024 | $1,930,501 | April 15, 2020 | March 31, 2025 | SMITH, STEPHEN EDWARD PAUCHA | reporter.nih.gov |
| Engineering Bacteriophage T4 as a Targeted Gene Therapy Drug for in vivo HIV Cure | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,929,060 | June 1, 2024 | March 31, 2029 | RAO, VENIGALLA B. | reporter.nih.gov |
| Biology and Biotechnology of Cell and Gene Therapy | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,928,667 | July 1, 2021 | June 30, 2026 | SCHAFFER, DAVID V | reporter.nih.gov |
| Gene therapy for Alzheimer's disease using virally delivered Aβ variants | NIH | National Institute on Aging | 2021 to 2022 | $1,928,130 | August 15, 2021 | July 31, 2024 | JANKOWSKY, JOANNA L | reporter.nih.gov |
| Development and validation of novel mouse models and expression vectors for characterizing severe alpha-thalassemia pathophysiology and evaluating gene therapy approaches. | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,927,121 | June 1, 2023 | May 31, 2027 | RIVELLA, STEFANO | reporter.nih.gov |
| Development of miR-27a* for the Treatment of Head and Neck Squamous Cell Carcinoma | NIH | National Institute of Dental & Craniofacial Research | 2023 to 2025 | $1,926,899 | July 15, 2023 | July 31, 2028 | LAI, STEPHEN Y | reporter.nih.gov |
| Engineering T Cell Adoptive Therapy for Glioblastoma | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,925,432 | August 1, 2023 | April 30, 2028 | DUNN, GAVIN PETER | reporter.nih.gov |
| Label-free imaging of CAR T cell metabolism | NIH | National Cancer Institute | 2023 to 2025 | $1,924,868 | August 1, 2023 | July 31, 2028 | SKALA, MELISSA CAROLINE | reporter.nih.gov |
| Targeted expression of factor VIII in liver sinusoidal endothelial cells for gene therapy for hemophilia A | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,923,201 | September 1, 2020 | July 31, 2025 | SABATINO, DENISE E | reporter.nih.gov |
| Alpha cell conversion to beta cells in non-human primates | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $1,922,925 | September 30, 2018 | June 30, 2025 | GITTES, GEORGE K. | reporter.nih.gov |
| CAR T CELLS ENGINEERED TO KILL HIV-INFECTED CELLS WHILE SECRETING BROADLY NEUTRALIZING ANTIBODIES | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,920,000 | March 25, 2020 | February 28, 2026 | LAWSON, BRIAN | reporter.nih.gov |
| Validation of analytical methods for quantification of a pentasaccharide biomarker in efficacy assessment of AVV treatment for GM1 gangliosidosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,917,563 | March 1, 2021 | February 28, 2026 | JIANG, XUNTIAN | reporter.nih.gov |
| Role of Heat Shock Protein 70 as a Mediator and Therapeutic Target in T-cell Lymphomas | NIH | National Cancer Institute | 2022 to 2025 | $1,917,273 | July 20, 2022 | June 30, 2027 | ORLOWSKI, ROBERT ZYGMUNT | reporter.nih.gov |
| Exploring the pathophysiology and treatment of LCHADD retinopathy | NIH | National Eye Institute | 2021 to 2025 | $1,913,450 | September 1, 2021 | July 31, 2026 | GILLINGHAM, MELANIE B | reporter.nih.gov |
| BRAIN Viral Vector Services and Distribution Core | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,909,678 | September 1, 2021 | August 31, 2026 | RITOLA, KIMBERLY | reporter.nih.gov |
| Novel multipronged Immunovirotherapy Approach for GBM Treatment | NIH | National Cancer Institute | 2021 to 2025 | $1,909,428 | March 1, 2021 | February 28, 2027 | GALANIS, EVANTHIA | reporter.nih.gov |
| Ligand-mediated, vehicle-free delivery of small RNAs | NIH | National Cancer Institute | 2021 to 2025 | $1,908,192 | April 1, 2018 | August 31, 2028 | KASINSKI, ANDREA L | reporter.nih.gov |
| Genetic engineering of kidney allografts by ex vivo perfusion delivery of adeno-associated viral vectors | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,903,303 | July 19, 2022 | April 30, 2027 | BARBAS, ANDREW SERGHIOS | reporter.nih.gov |
| A Nanocarrier Platform for Targeting Schlemm's Canal Cells | NIH | National Eye Institute | 2022 to 2025 | $1,902,955 | September 30, 2022 | July 31, 2026 | JOHNSON, MARK | reporter.nih.gov |
| Translational studies on cerebrospinal fluid (CSF)-directed gene therapy for global neurometabolic brain disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $1,902,904 | April 1, 2019 | March 31, 2026 | WOLFE, JOHN H | reporter.nih.gov |
| Engineered BacNav and BacCav for Improved Excitability and Contraction | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $1,900,343 | May 1, 2022 | January 31, 2027 | BURSAC, NENAD | reporter.nih.gov |
| Characterizing and testing the efficacy of AAV-mediated gene therapy in a sheep model of CLN1 disease. | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,898,833 | August 1, 2022 | June 30, 2027 | COOPER, JONATHAN D | reporter.nih.gov |
| Viral and Host Determinants of Parvovirus Replication | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,888,216 | January 27, 2020 | December 31, 2025 | QIU, JIANMING | reporter.nih.gov |
| Non-Activated Natural Killer Cell Engineering For Enhanced Cytotoxic Potential | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,881,602 | April 20, 2021 | June 30, 2026 | CHIU, MICHAEL | reporter.nih.gov |
| Preclinical Development of a Novel Gene Therapeutic for Inclusion Body Myositis | NIH | National Institute on Aging | 2022 to 2023 | $1,877,616 | September 30, 2022 | August 31, 2025 | RODGERS, BUEL | reporter.nih.gov |
| NINDS Network for Excellence in Neuroscience: Clinical Research Site at UC Davis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,876,070 | July 6, 2018 | June 30, 2028 | MCDONALD, CRAIG M. | reporter.nih.gov |
| Engineering Efficient and Controllable Base Editors | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $1,873,110 | May 1, 2021 | April 30, 2026 | KOHLI, RAHUL MANU | reporter.nih.gov |
| Epigenetic Therapy to Treat Radiation-induced Xerostomia | NIH | National Institute of Dental & Craniofacial Research | 2022 to 2025 | $1,871,213 | July 1, 2022 | March 31, 2027 | LOMBAERT, ISABELLE M.A. | reporter.nih.gov |
| University of Rochester Clinical Site within the NEXT Network of Clinical Trials | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,869,169 | July 1, 2018 | June 30, 2028 | HOLLOWAY, ROBERT G. | reporter.nih.gov |
| Advancing CNS drug delivery via epigenetic modulation | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,868,790 | January 18, 2023 | December 31, 2026 | PAN, DAO | reporter.nih.gov |
| Combination Gene Therapy for Treatment of Canine Mucopolysaccharidosis Type I | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 to 2025 | $1,867,960 | May 5, 2023 | February 29, 2028 | WANG, RAYMOND YU JEANG | reporter.nih.gov |
| Understanding the influence of bone-metastatic prostate cancer and mesenchymal stromal cells on γδ T cells, in the bone microenvironment. | NIH | National Cancer Institute | 2021 to 2024 | $1,866,870 | March 9, 2020 | August 31, 2025 | ABATE-DAGA, DANIEL | reporter.nih.gov |
| AAV-mediated gene therapy for CNS disease correction in feline NPC1 disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $1,866,121 | December 15, 2020 | November 30, 2023 | VITE, CHARLES H | reporter.nih.gov |
| Sonogenetics 2.0 | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,864,333 | July 15, 2023 | June 30, 2028 | CHEN, HONG | reporter.nih.gov |
| Next Generation Immunotherapies for Pediatric Cancers | NIH | National Cancer Institute | 2024 to 2025 | $1,863,847 | September 9, 2024 | August 31, 2031 | MACKALL, CRYSTAL | reporter.nih.gov |
| CONTROL OF T CELL SYNAPSE STABILIZATION AND SIGNALING | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,862,532 | September 15, 2002 | July 31, 2028 | KRUMMEL, MATTHEW F | reporter.nih.gov |
| Allogeneic BAFF Ligand Based CAR T Cells as a Novel Therapy for B Cell Malignancies | NIH | National Cancer Institute | 2023 to 2025 | $1,861,249 | July 1, 2023 | August 31, 2027 | GIBBONS, HUNTER RAMSDELL | reporter.nih.gov |
| Exercise as an Immune Adjuvant for Gamma Delta T-cell Therapies in Hematologic Malignancies | NIH | National Cancer Institute | 2023 to 2025 | $1,860,326 | April 1, 2023 | March 31, 2028 | SIMPSON, RICHARD J | reporter.nih.gov |
| Brain-Wide Genome Editing Enabled by Intravenously Administered Non-Viral Nanovectors As a Potential Therapy for Alzheimer’s Disease | NIH | National Institute on Aging | 2023 | $1,860,250 | May 15, 2023 | April 30, 2026 | GONG, SHAOQIN - | reporter.nih.gov |
| Broadening access with an Armamentarium Vector Core Powered by Inclusive Research Experiences | NIH | National Institute of Mental Health | 2022 to 2024 | $1,856,392 | August 1, 2022 | June 30, 2025 | SHAY, TIMOTHY FRANCIS | reporter.nih.gov |
| Allele-specific inactivation for dominant negative NEFL Mutations | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,855,975 | August 15, 2021 | June 30, 2027 | JUDGE, LUKE M | reporter.nih.gov |
| Advanced Delivery Platforms for Base Editing In Vivo | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $1,853,586 | September 1, 2023 | August 31, 2027 | SONTHEIMER, ERIK J. | reporter.nih.gov |
| Targeting lung tumors expressing mutant p53 with oncolytic viruses and suicide genes | NIH | National Cancer Institute | 2021 to 2024 | $1,853,575 | July 1, 2020 | June 30, 2025 | DEB, SUMITRA | reporter.nih.gov |
| Advancing next-generation CAR-NK therapies targeting CD5 positive T cell malignancies to the clinic | NIH | National Cancer Institute | 2025 | $1,847,485 | September 19, 2025 | August 31, 2029 | REZVANI, KATY | reporter.nih.gov |
| High throughput CAR-T potency assay based on functional and transcriptional measurements on single cell co-cultures | NIH | National Cancer Institute | 2024 to 2025 | $1,847,334 | May 1, 2024 | April 30, 2026 | YELLEN, BENJAMIN BIRON | reporter.nih.gov |
| Adrenergic modulation of cellular immune functions in CAR T cell-induced cytokine release syndrome | NIH | National Cancer Institute | 2021 to 2024 | $1,842,599 | January 1, 2020 | January 2, 2024 | STAEDTKE, VERENA | reporter.nih.gov |
| Oligodendrocyte-focused rAAV gene therapy strategies for Canavan disease and Leukodystrophies | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,838,158 | September 1, 2012 | January 31, 2030 | GAO, GUANGPING | reporter.nih.gov |
| Making Oligonucleotides Better Biopharmaceuticals by Steric Protection | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,833,125 | September 1, 2017 | March 31, 2027 | ZHANG, KE | reporter.nih.gov |
| Novel bioengineered microRNA therapeutics for lung cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,829,330 | December 1, 2018 | July 31, 2029 | YU, AIMING | reporter.nih.gov |
| CAR NKT Cell Immunotherapy of Neuroblastoma | NIH | National Cancer Institute | 2021 to 2025 | $1,828,377 | June 12, 2021 | May 31, 2026 | METELITSA, LEONID S | reporter.nih.gov |
| Intravenous VSV virotherapy in lymphoma | NIH | National Cancer Institute | 2023 to 2025 | $1,828,271 | May 11, 2023 | April 30, 2028 | PENG, KAH-WHYE | reporter.nih.gov |
| Use of Focused ultrasound stimulated blood brain barrier opening for CNS HIV/SIV reservoir reduction | NIH | National Institute on Drug Abuse | 2025 | $1,825,990 | September 1, 2025 | May 31, 2030 | MOHAN, MAHESH | reporter.nih.gov |
| Dissecting AAV silencing in humanized mice | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,823,990 | February 1, 2023 | January 31, 2027 | BISSIG, KARL-DIMITER | reporter.nih.gov |
| Retinal structure, function and response to gene therapy | NIH | National Eye Institute | 2021 to 2025 | $1,823,500 | March 1, 2018 | February 28, 2029 | MORGAN, JESSICA I.W. | reporter.nih.gov |
| Programming multi-pronged immune response to glioblastoma with IL-13Ra2/TGF-b CAR-T cell therapy. | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,820,675 | March 1, 2023 | January 31, 2028 | CHEN, YVONNE YU-HSUAN | reporter.nih.gov |
| Precision genome editing in vivo to treat retinal diseases | NIH | National Eye Institute | 2023 to 2025 | $1,815,507 | March 1, 2023 | February 28, 2026 | PALCZEWSKI, KRZYSZTOF | reporter.nih.gov |
| Linking insertional mutagenesis and cell function to improve CAR T cell therapy | NIH | National Cancer Institute | 2021 to 2023 | $1,813,460 | June 1, 2019 | April 30, 2024 | BUSHMAN, FREDERIC D | reporter.nih.gov |
| Cell-directed gene therapy for pain recovery after surgery and inflammation | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,809,441 | January 15, 2022 | December 31, 2026 | ROMERO-SANDOVAL, E. ALFONSO | reporter.nih.gov |
| A single dose anti-scarring therapeutic for the cornea | NIH | National Eye Institute | 2023 to 2024 | $1,799,926 | September 30, 2023 | July 1, 2025 | WILLIAMS, TERE M. | reporter.nih.gov |
| Trispecific CAR-T cells targeting CD19, CD20 and CD22 to treat B-cell malignancies | NIH | National Cancer Institute | 2023 to 2025 | $1,797,355 | July 21, 2023 | June 30, 2028 | VASU, SUMITHIRA | reporter.nih.gov |
| Improved Delivery of Gene Therapies to the Central Nervous System by Focused Ultrasound-Mediated Disruption of the Blood-Brain Barrier | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,791,568 | May 1, 2022 | March 31, 2027 | TODD, NICHOLAS E. | reporter.nih.gov |
| Therapeutic Strategy to Treat Alzheimer's Disease by VGF Delivery into Brain | NIH | National Institute on Aging | 2023 to 2025 | $1,787,026 | September 16, 2023 | May 31, 2028 | SINGH, JAGDISH | reporter.nih.gov |
| Controllable base editing therapy for DMD | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,786,579 | September 1, 2023 | August 31, 2027 | HAN, RENZHI | reporter.nih.gov |
| Regulation of eDHFR-tagged proteins with trimethoprim PROTACs | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $1,784,694 | September 1, 2023 | June 30, 2027 | SELLMYER, MARK A | reporter.nih.gov |
| Mechanoimmunological interactions between TCR-T cells and tumor fibrotic microenvironment | NIH | National Cancer Institute | 2023 to 2025 | $1,784,080 | May 9, 2023 | April 30, 2028 | ZHAO, RUOGANG | reporter.nih.gov |
| Targeted RNA delivery using ribonucleoprotein | NIH | National Cancer Institute | 2023 to 2025 | $1,782,041 | May 1, 2023 | April 30, 2027 | GAO, XIAOHU | reporter.nih.gov |
| A Novel Therapeutic to Promote Corneal Repair | NIH | National Eye Institute | 2023 to 2025 | $1,779,892 | September 30, 2023 | August 31, 2026 | KRAMER, ADAM HILDYARD | reporter.nih.gov |
| Synthetic epigenetic circuits: tunable cell fate switches controlled by dynamic and combinatorial inputs | NIH | National Cancer Institute | 2021 to 2025 | $1,779,251 | April 1, 2021 | March 31, 2027 | LIM, WENDELL A | reporter.nih.gov |
| Ameliorating off-target toxicities of CAR T cells by engineering NOT gates | NIH | National Cancer Institute | 2022 to 2025 | $1,777,692 | August 1, 2022 | July 31, 2027 | LIM, WENDELL A | reporter.nih.gov |
| A Novel Adenoviral-Permissive, Immunocompetent Hamster Model to Evaluate Oncolytic Adenoviral Therapy for Glioblastoma | NIH | National Cancer Institute | 2021 to 2024 | $1,776,988 | April 1, 2020 | March 31, 2025 | LANG, FREDERICK F | reporter.nih.gov |
| NextGen - CHOP | NIH | National Cancer Institute | 2022 to 2025 | $1,775,451 | June 1, 2025 | May 31, 2026 | MARIS, JOHN M | reporter.nih.gov |
| Prevention of corneal transplant rejection using AAV-BDRK-401 therapy | NIH | National Eye Institute | 2024 to 2025 | $1,769,317 | September 30, 2020 | August 31, 2027 | GILGER, BRIAN C | reporter.nih.gov |
| Chemical engineering of therapeutic RNAs for extrahepatic delivery | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,767,125 | May 1, 2019 | May 31, 2030 | KHVOROVA, ANASTASIA | reporter.nih.gov |
| POTENTIATION OF ANTI-TUMOR IMMUNITY BY ONCOLYTIC VIRUS IN SITU VACCINATION | NIH | National Cancer Institute | 2023 to 2025 | $1,766,542 | April 1, 2023 | March 31, 2028 | ZAMARIN, DMITRIY | reporter.nih.gov |
| In vivo hematopoietic stem cell genetic modification by viral particles | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,764,905 | September 9, 2024 | May 31, 2028 | BAUER, DANIEL EVAN | reporter.nih.gov |
| Development of gene therapy product for treating MPS IIIB | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,762,240 | September 1, 2024 | August 31, 2027 | MCCARTY, DOUGLAS M | reporter.nih.gov |
| Suprachoroidal nonviral gene transfer of engineered VEGF antagonists | NIH | National Eye Institute | 2021 to 2023 | $1,760,895 | February 1, 2020 | January 31, 2025 | CAMPOCHIARO, PETER A | reporter.nih.gov |
| Establishing the POROS Intracellular Delivery System as a Platform for Cellular Therapeutics | NIH | National Cancer Institute | 2021 to 2022 | $1,760,111 | September 10, 2018 | August 31, 2024 | BINKLEY, MICHAEL M | reporter.nih.gov |
| A Massive Library of AAVs to Target Transcriptionally-Defined Primate Cell Types | NIH | National Institute of Mental Health | 2021 | $1,759,059 | September 1, 2019 | June 30, 2023 | STAUFFER, WILLIAM RICHARD | reporter.nih.gov |
| In vivo PET imaging of novel engineered AAVs informs capsid design in Alzheimer's Disease | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2022 | $1,758,320 | August 1, 2019 | April 30, 2024 | FERRARA, KATHERINE W | reporter.nih.gov |
| Preclinical development of CM-CX1 for the treatment of ovarian clear cell and renal cell carcinomas | NIH | National Cancer Institute | 2021 to 2023 | $1,756,207 | September 8, 2021 | August 31, 2025 | MURAD, JOANA M | reporter.nih.gov |
| PyroTIMER Technology: Enabling T-Cell Persistence in Immunosuppressive Tumor Microenvironments | NIH | National Cancer Institute | 2024 to 2025 | $1,747,620 | September 23, 2024 | August 31, 2026 | BAGATI, ARCHIS | reporter.nih.gov |
| Restoring Immune Tolerance in a Model of Multiple Sclerosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,740,026 | January 1, 2017 | January 31, 2028 | KEELER, GEOFFREY D | reporter.nih.gov |
| Improving CAR-T efficacy against solid tumors by expanding lymph node reservoirs of “stem-like” CAR-T cells | NIH | National Cancer Institute | 2023 to 2025 | $1,734,139 | July 1, 2023 | June 30, 2028 | SRIVASTAVA, SHIVANI | reporter.nih.gov |
| A multimodal delivery and treatment approach for Acute Lung Injury | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,731,773 | April 5, 2020 | March 31, 2025 | DEAN, DAVID A | reporter.nih.gov |
| Endothelial-Leukocyte Adhesion in CAR T Cell Treatment Associated Neurotoxicity | NIH | National Cancer Institute | 2023 to 2025 | $1,730,791 | September 22, 2023 | August 31, 2028 | GUST, JULIANE | reporter.nih.gov |
| Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL | NIH | National Cancer Institute | 2023 to 2024 | $1,730,616 | September 9, 2020 | July 31, 2025 | DESAI, AVINASH | reporter.nih.gov |
| Mechanisms of mineralocorticoid receptor antagonism on inflammation in muscular dystrophy | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,726,538 | January 1, 2022 | December 31, 2026 | RAFAEL-FORTNEY, JILL A | reporter.nih.gov |
| Develop Conditionally Armored CAR Macrophage Therapy for Pancreatic Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,725,994 | September 5, 2023 | July 31, 2028 | HOU, PINGPING | reporter.nih.gov |
| SCGE Disease Models Studies Supplement: Evaluation of prime editing for the amelioration of alpha-1-antitrypsin deficiency in murine and porcine models. | NIH | Office of the Director, National Institutes of Health | 2021 to 2022 | $1,724,497 | September 20, 2018 | July 31, 2024 | CARLSON, DANIEL FRED | reporter.nih.gov |
| Accelerating Gene Therapy and Editing with Advanced MS-Based Data Analysis for Nonstandard and Hybrid Nucleotide Sequences | NIH | National Institute of General Medical Sciences | 2023 to 2024 | $1,721,266 | July 5, 2023 | June 30, 2025 | JOHNSON, GEORGE HALL | reporter.nih.gov |
| A single mutation-independent AAV gene therapy for the treatment of autosomal-dominant retinitis pigmentosa. | NIH | National Eye Institute | 2024 to 2025 | $1,719,904 | September 30, 2024 | August 31, 2027 | JAYAGOPAL, ASHWATH | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| University of Pennsylvania | Philadelphia, PA | 66 | $106.7 million | 0 | $0 |
| Stanford University | Stanford, CA | 57 | $64.5 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 53 | $61.4 million | 0 | $0 |
| Children's Hosp of Philadelphia | Philadelphia, PA | 25 | $60.3 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 42 | $52 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 38 | $47.8 million | 0 | $0 |
| Yale University | New Haven, CT | 25 | $45.9 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 32 | $44.8 million | 0 | $0 |
| Duke University | Durham, NC | 40 | $38.7 million | 0 | $0 |
| Fred Hutchinson Cancer Center | Seattle, WA | 24 | $37.9 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 26 | $37.6 million | 0 | $0 |
| Washington University | Saint Louis, MO | 38 | $36.2 million | 0 | $0 |
| University of Florida | Gainesville, FL | 30 | $35.8 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 18 | $35.7 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 27 | $34.7 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 32 | $34.1 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 25 | $33.7 million | 0 | $0 |
| University of California at Davis | Davis, CA | 22 | $32 million | 0 | $0 |
| Broad Institute, Inc. | Cambridge, MA | 10 | $31.6 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 27 | $31.3 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 10 | $31.1 million | 0 | $0 |
| University of TX MD Anderson Can CTR | Houston, TX | 26 | $30.8 million | 0 | $0 |
| University of California-Berkeley | Berkeley, CA | 12 | $28.3 million | 0 | $0 |
| Medical College of Wisconsin | Milwaukee, WI | 10 | $27.1 million | 0 | $0 |
| Ohio State University | Columbus, OH | 21 | $26.9 million | 0 | $0 |
| ST. Jude Children's Research Hospital | Memphis, TN | 17 | $26.7 million | 0 | $0 |
| Sloan-Kettering Inst Can Research | New York, NY | 20 | $26.4 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 18 | $25.4 million | 0 | $0 |
| Emory University | Atlanta, GA | 24 | $24.5 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 31 | $24.5 million | 0 | $0 |
| Beckman Research Institute/city of Hope | Duarte, CA | 16 | $23.8 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 12 | $22.2 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 17 | $21.5 million | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 17 | $20.4 million | 0 | $0 |
| University of Washington | Seattle, WA | 19 | $19.7 million | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 20 | $19.2 million | 0 | $0 |
| Massachusetts Eye and Ear Infirmary | Boston, MA | 8 | $19.1 million | 0 | $0 |
| Seattle Children's Hospital | Seattle, WA | 14 | $18.4 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 13 | $18.2 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 17 | $17.6 million | 0 | $0 |
| University of Missouri-Columbia | Columbia, MO | 9 | $17.5 million | 0 | $0 |
| Cincinnati Childrens Hosp Med CTR | Cincinnati, OH | 12 | $16.6 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 13 | $16.2 million | 0 | $0 |
| University of Miami School of Medicine | Coral Gables, FL | 17 | $15.8 million | 0 | $0 |
| Allen Institute | Seattle, WA | 5 | $14.9 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 10 | $14.8 million | 0 | $0 |
| Indiana University Indianapolis | Indianapolis, IN | 14 | $14 million | 0 | $0 |
| Dana-Farber Cancer Inst | Boston, MA | 10 | $14 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 12 | $13.9 million | 0 | $0 |
| California Institute of Technology | Pasadena, CA | 6 | $13.5 million | 0 | $0 |
| University of Rochester | Rochester, NY | 9 | $13.5 million | 0 | $0 |
| Vanderbilt University | Nashville, TN | 15 | $13.1 million | 0 | $0 |
| Michigan State University | East Lansing, MI | 10 | $12.8 million | 0 | $0 |
| Beth Israel Deaconess Medical Center | Boston, MA | 7 | $12.3 million | 0 | $0 |
| Trustees of Boston University | Boston, MA | 11 | $11.7 million | 0 | $0 |
| Georgia Tech Research Corporation | Atlanta, GA | 12 | $11.6 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 9 | $11 million | 0 | $0 |
| Research Inst Nationwide Children's Hosp | Columbus, OH | 13 | $10.7 million | 0 | $0 |
| Northeastern University | Boston, MA | 4 | $10.7 million | 0 | $0 |
| University of Chicago | Chicago, IL | 11 | $10.5 million | 0 | $0 |
| Massachusetts Institute of Technology | Cambridge, MA | 12 | $10.4 million | 0 | $0 |
| Institute for Molecular Medicine | Huntington Beach, CA | 1 | $10.3 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 11 | $10.2 million | 0 | $0 |
| University of Illinois at Urbana-Champaign | Urbana, IL | 5 | $9.7 million | 0 | $0 |
| University of Arizona | Tucson, AZ | 6 | $9.7 million | 0 | $0 |
| H. Lee Moffitt Cancer CTR & Res Inst | Tampa, FL | 8 | $9.4 million | 0 | $0 |
| University of Southern California | Los Angeles, CA | 8 | $9.3 million | 0 | $0 |
| Oregon State University | Corvallis, OR | 5 | $9.2 million | 0 | $0 |
| Wake Forest University Health Sciences | Winston-Salem, NC | 9 | $8.6 million | 0 | $0 |
| Methodist Hospital Research Institute | Houston, TX | 8 | $8.2 million | 0 | $0 |
| Virginia Commonwealth University | Richmond, VA | 4 | $8 million | 0 | $0 |
| New York University | New York, NY | 5 | $7.7 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 6 | $7.4 million | 0 | $0 |
| Scripps Research Institute, the | La Jolla, CA | 4 | $7.3 million | 0 | $0 |
| University of Kansas Medical Center | Kansas City, KS | 9 | $7.2 million | 0 | $0 |
| University of Nebraska Medical Center | Omaha, NE | 6 | $7.1 million | 0 | $0 |
| J. David Gladstone Institutes | San Francisco, CA | 7 | $7.1 million | 0 | $0 |
| Black Canyon Consulting LLC | Fairfax, VA | 1 | $6.9 million | 0 | $0 |
| Neurogt, Inc. | Chapel Hill, NC | 6 | $6.9 million | 0 | $0 |
| Purdue University | West Lafayette, IN | 6 | $6.8 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 6 | $6.7 million | 0 | $0 |
| Northwestern University | Chicago, IL | 4 | $6.6 million | 0 | $0 |
| Augusta University | Augusta, GA | 6 | $6.4 million | 0 | $0 |
| William Marsh Rice University | Houston, TX | 10 | $6.4 million | 0 | $0 |
| University of Iowa | Iowa City, IA | 7 | $6.3 million | 0 | $0 |
| University of South Florida | Tampa, FL | 8 | $6.3 million | 0 | $0 |
| Amplo Biotechnology, Inc. | Towson, MD | 2 | $6.2 million | 0 | $0 |
| Medical Science & Computing, LLC | Rockville, MD | 1 | $6.1 million | 0 | $0 |
| University of Delaware | Newark, DE | 4 | $6 million | 0 | $0 |
| Fred Hutchinson Cancer Research Center | Seattle, WA | 13 | $6 million | 0 | $0 |
| Lovelace Biomedical Research Institute | Albuquerque, NM | 3 | $6 million | 0 | $0 |
| Case Western Reserve University | Cleveland, OH | 8 | $5.8 million | 0 | $0 |
| Hackensack University Medical Center | Hackensack, NJ | 2 | $5.6 million | 0 | $0 |
| Acurastem, Inc. | Pasadena, CA | 2 | $5.6 million | 0 | $0 |
| University of Connecticut | Storrs, CT | 4 | $5.3 million | 0 | $0 |
| Cartesian Therapeutics, Inc. | Gaithersburg, MD | 4 | $5.3 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 6 | $5.3 million | 0 | $0 |
| Cornell University | Ithaca, NY | 5 | $5.2 million | 0 | $0 |
| Marpam Pharma, LLC | St. Paul, MN | 5 | $5.1 million | 0 | $0 |
| Children's Research Institute | Washington, DC | 3 | $5 million | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 1,021 | $636,811,219 | 0 | $0 |
| 2024 | 986 | $519,702,286 | 0 | $0 |
| 2023 | 870 | $454,810,294 | 0 | $0 |
| 2022 | 809 | $396,477,937 | 0 | $0 |
| 2021 | 723 | $365,669,746 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.